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Chapter 1 
 
General introduction 
 
This introduction is partly based on: 
 
CPM Reutelingsperger, E Dumont, PW Thimister, H van Genderen, H Kenis, S 
van de Eijnde, G Heidendal and L Hofstra. Visualization of cell death in vivo 
with the annexin A5 imaging protocol. Journal of Immunological Methods. 
265(1-2):123-32 (2002). 
 
H van Genderen, H Kenis, E Dumont, W van Heerde, L Hofstra and CPM 
Reutelingsperger. Cell proliferation and apoptosis. Chapter 7, Membrane 
alterations in dying cells. Editors, D Hughes and H Mehmet. Taylor & Francis, 
(2003). 
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The annexins 
The Annexins are a family of membrane binding proteins that share structural 
properties and biological activities associated with membrane related 
processes1. Each annexin consists of a core structure of four domains of 70 
amino acids with the exception of annexin A6 which consists of two core 
structures connected via a short peptide linker 2. Members of the annexin family 
are able to bind to negatively charged phospholipids in the presence of calcium 
ions. In solution annexin molecules are present in the form of monomers. After 
binding to a phospholipid surface some annexin members remain bound as 
monomers while other annexins form a two-dimensional crystal lattice by 
protein-protein interactions. Two-dimensional lattice formation has been found 
to occur with the human annexin A4, annexin A5 and annexin A6 3-6. Some 
annexins can interact with other proteins via their amino terminal tail, which is 
different in length and amino acid composition for each family member. For 
instance annexin A1 interacts with S100A11 while annexin A2 interacts with 
S100A10 7-10. The latter can also form a tetramer complex consisting of two 
annexin A2 and two S100A10 proteins. Annexins are pleiotropic proteins 
meaning that there function is dependent on tissue location and changes in the 
surrounding environment. For example, annexin A1 has been proposed to act 
intracellularly as an inhibitor of phospholipase A2 by competing for 
phosphatidylserine (PS) binding sites 11-13. Extracellular annexin A1 binds to 
neutrophils possibly via the amino terminal tail and accelerates apoptosis via 
the induction of a calcium influx into the cell 14. Pleiotropy is further displayed by 
annexin A2. In the cytosol annexin A2 plays a role in vesicle trafficking during 
endocytosis 15, 16 but in the extracellular environment annexin A2 acts as a 
membrane “receptor” for tissue plasminogen activator 17 or as an opsonin for 
the phagocytosis of apoptotic cells 18. Knockout mice have been created for 
annexin A1 and annexin A2 in order to examine the in vivo function of these 
proteins. Analysis of the annexin A1 knockout mouse has demonstrated that 
annexin A1 plays a role in inflammation 19. Examination of the annexin A2 
knockout mouse showed the involvement of annexin A2 in the coagulation 
process 20. 
 
Exocytosis of annexins 
Annexins are considered cytosolic proteins because they lack a 5’-leader 
sequence in their messenger RNA. However, annexin A1, annexin A2 and 
annexin A5 have been found in the circulation indicating that they are released 
into the extracellular environment 21-24. Proteins that are released into the 
extracellular environment contain a leader sequence in their messenger RNA 
that directs them to the endoplasmatic reticulum (ER). Synthesized protein is 
then transported via the Golgi apparatus to the plasma membrane and 
subsequently into the extracellular environment 25. A possible explanation for 
the presence of annexins in the circulation might be the release of cytosolic 
content from necrotic cells into the surrounding environment. There is however 
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evidence for the existence of protein release pathways independent of the ER 
and Golgi apparatus. For instance, interleukin-1β and fibroblast growth factor 1 
(FGF-1) are proteins that lack a signal peptide and they are present in the 
circulation. Several non-classical exocytosis pathways have been proposed for 
the release of interleukin-1β and FGF-1 26. The plasma membrane located 
ABC-A1 transporter has been suggested to play a role in the release of 
interleukin-1β 27. While release of FGF-1 is suggested to be mediated by a 
cytosol located multi-protein complex comprised of Cu2+, S100A13, 
synaptotagmin-1 p40 and FGF-1 28. 
Similar to interleukin-1β and FGF-1, annexins have been proposed to be 
released by non-classical exocytosis pathways. Annexin A1, present in pituitary 
folliculo-stellate cells, has been found to be released into the extracellular 
environment when these cells are treated with the glucocorticoid 
dexamethasone. Release of annexin A1 occurs after serine-phosphorylation 
and has been proposed to be mediated by the ABC-A1 transporter 29-31. The 
release mechanism for annexin A2 has not been elucidated but release occurs 
during a brief period of temperature stress 32. The circumstances under which 
annexin A5 is released and the mechanism responsible for this release are at 
present unknown.  
 
Structure and PS-binding properties of annexin A5 
Annexin A5, a member of the annexin family, is a protein that binds calcium-
dependently to PS-expressing membranes 33, 34. The tertiary structure of the 
soluble form of Annexin A5 has been solved with X-ray crystallography by 
Huber et al. (Fig. 1a) 35. X-ray crystallography has revealed that the tertiary 
structure of annexin A5 consists of a core of four domains that are arranged in a 
cyclic array. This arrangement gives the molecule a slightly curved shape with a 
convex and a concave face (Fig. 1a). Each domain consists of 5 helices linked 
to each other via a short turn. The calcium- and PS binding sites are located at 
the convex, membrane-facing side of the protein 36. A short amino terminal tail 
is located at the concave site of the molecule. 
The Annexin A5 core contains potential post-translational modification sites that 
can be O-glycosylated. In addition, the amino terminal tail contains two 
threonine residues which are potential sites for phosphorylation. However, 
annexin A5 has not been found to be glycosylated or phosphorylated. The 
amino terminal tail contains the only post translational modification of annexin 
A5: an alanine residue located acetylation 37, 38. 
Electron crystallography of membrane-bound annexin A5 has revealed that 
annexin A5 molecules can associate with each other via protein-protein 
interactions (Fig. 1b) 39. In solution annexin A5 molecules are monomers, but 
upon binding to a PS-containing surface they self-assemble into a two-
dimensional crystal lattice. The annexin A5 trimer is the basic building block of 
the two-dimensional crystal lattice (Fig. 1c). The two-dimensional crystal lattice 
consists of trimers, dimers of trimers and trimers of trimers arranged with p3 or 
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p6 symmetry 40. The type of two-dimensional crystal that is formed depends on 
the content of PS in the membrane. The two-dimensional lattice with p6 
symmetry forms at a PS content that closely matches that found in biological 
membranes. The crystal with p3 symmetry is formed at a phospholipid 
membrane containing a higher PS content 40. 
Electron crystallography has further revealed that the membrane bound form of 
the annexin A5 monomer has nearly the same structure as the soluble form 41. 
This suggests that the various domains have an unequal distance to the 
phospholipid membrane surface. Both electron crystallographic data and atomic 
force microscopy suggest that domain III is the most distant from the membrane 
surface and domain II the closest 41, 42. The convex shape of membrane bound 
annexin A5 potentially influences the shape of the PS-expressing membrane 
surface. All four domains contain a calcium binding motif making it possible that 
membrane-bound annexin A5 influences the PS-expressing membrane surface 
to adopt a shape that is complementary to the convex shape of the annexin A5 
molecule 41. 
Zinc ions affect the calcium-dependent binding of annexin A5 to PS-expressing 
membranes 34. Annexin A5 does not bind to PS-containing membrane surfaces 
when zinc ions are present and calcium ions are absent. However, the 
presence of zinc ions in addition to calcium increases the binding affinity of 
annexin A5 for PS. The zinc-induced increase in binding affinity has been 
attributed to a cysteine residue in the annexin A5 molecule located at amino 
acid site 315 (unpublished data, Reutelingsperger et al.). A zinc ion possibly 
binds to the cysteine-315 residue and influences the calcium-dependent binding 
affinity via an unknown mechanism. Zinc ions are present in the circulation in a 
concentration of 12-16 µmol L-1 43. This possibly leads to an increase in binding 
affinity of annexin A5 for PS-expressing membrane surfaces when annexin A5 
is present in the circulation. 
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Figure 1, Molecular structure of annexin A5. Side view of a model of a monomeric 
annexin A5 molecule (a), top view of a model of three annexin A5 molecules organized 
in a membrane bound trimer, each annexin A5 molecule is oriented in such a manner 
that domain II is localized in the inside and domain IV at the outside of the trimer (b) 
[Adapted from Sopkova et al, 1993; numbering of annexin A5 domains according to 
Huber et al, 1990], (c) top view of a model of an annexin A5 trimer building block 
organized into a dimer of trimers and a trimer of trimers with p6 and p3 symmetry 
[Adapted from Oling et al, 2001]. 
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Biological functions of annexin A5 
Similar to other annexins, annexin A5 has been found to be a pleiotropic 
protein. For example, membrane interactions of annexin A5 can occur in a 
calcium-dependent and independent manner. In addition, membrane 
interactions can occur when annexin A5 is present in the intra- and extracellular 
environment. 
Data obtained from in vitro studies have suggested that annexin A5 functions in 
the intracellular environment as an inhibitor of phospholipase A2. 
Phospholipase A2 is an enzyme that uses PS as a substrate in the formation of 
free fatty acid and 2-lysophospholipid 44. The free fatty acid in the form of 
arachidonic acid that is released by phospholipase A2 plays a role in signal 
transduction processes. Studies with artificial membranes or membranes 
derived from lysed cells show that binding of phospholipase A2 to PS-
containing membranes can be inhibited by annexin A5 45-47. Inhibition of 
phospholipase A2 activity by annexin A5 in these model systems occurs by 
competition for PS binding sites in a calcium-dependent manner. However, 
inhibition of phospholipase A2 by annexin A5 has not been studied in intact 
cellular systems. Thus, it is not known whether annexin A5 functions in the 
intracellular environment as an inhibitor of phospholipase A2. 
Annexins have been proposed to function as calcium conducting ion channels 
48, 49. How calcium ions are channeled through the plasma membrane has been 
an object of debate because annexins are peripheral membrane proteins. In an 
early model that attempted to explain the calcium conducting behavior of 
annexin A5 the calcium ions were supposed to flow through the hydrophilic 
center of the annexin molecule 50-52. In this model annexin A5 was located 
peripheral to the plasma membrane. Recent models have incorporated the idea 
that during calcium conduction the annexin molecule is inserted into the 
cytosolic site of the plasma membrane. Membrane insertion occurs in an 
environment with a very low calcium concentration. Moss et al. have shown that 
annexin A5 is able to associate with phospholipid membranes in a calcium-
independent manner in the presence of peroxide. They subsequently proposed 
that calcium is conducted across the membrane after a peroxide-induced 
insertion of annexin A5 into the plasma membrane at neutral pH 53. Another 
model is proposed by Haigler et al. In this model, calcium is conducted when 
human annexin A5 or hydra annexin B12 is inserted into the plasma membrane 
in a calcium-independent manner at a mildly acidic pH 54. The annexin B12 
molecule is proposed to change conformation so that the protein traverses the 
entire bilayer in such a manner that ions are able to cross the membrane 55. 
There is at present, however, no direct structural evidence from röntgen or 
electron diffraction analysis studies that support these models. 
The capacity of annexin A5 to bind calcium-dependently to PS has lead to the 
proposal that annexin A5 plays a role in the anti-thrombotic arm of blood 
coagulation 56. PS expressed by platelets supports the formation of the 
prothrombinase complex and the subsequent formation of thrombin 57. In vitro 
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studies have shown that shielding of PS binding sites by annexin A5 inhibits the 
formation of thrombin by the prothrombinase complex 58. Rand and co-workers 
have suggested that the anti-thrombotic behavior of annexin A5 plays a role in 
coagulation processes in the placenta of pregnant woman 59. Thrombosis is 
prevented in the placenta by shielding PS-expressing membrane surfaces 
through the formation of the two-dimensional crystal lattice of annexin A5. 
Disruption of the two-dimensional crystal lattice by anti-phospholipid antibodies 
is proposed to be responsible for recurrent pregnancy losses in women with the 
phospholipid antibody syndrome 60, 61. 
Brachvogel and co-workers have created an annexin A5 knock-out mouse to 
examine the in vivo function of annexin A5 62. Analysis of various physiological 
parameters of the knock-out mouse showed that the phenotype of the knock out 
mouse was not different when compared to the wild type mouse. A possible 
explanation for this result is that other annexins have an identical function as 
annexin A5. Possible candidates are annexins that have a close evolutionary 
relationship to annexin A5 such as annexin A4 and annexin A6 63. The creation 
of a knock-out mouse in which more than one annexin gene is deleted may be 
necessary to determine the function of annexin A5 in vivo. 
 
Cell death by apoptosis 
This thesis focuses on the cellular processes that are influenced by the calcium-
dependent binding of annexin A5 on PS-expressing cell surfaces. Cell surface 
expression of PS is one of the hallmarks of apoptosis. In several studies 
described in this thesis we have chosen to examine the interaction of annexin 
A5 with apoptotic PS-expressing cell surfaces. Therefore we describe in some 
detail the biochemical and cellular processes which occur during apoptosis in 
the following sections of the introduction. 
 
Apoptosis 
Unwanted cells in developing tissues and damaged or senescent cells are 
removed by phagocytes after induction of cell death 64-66. The most common 
form of cell death is apoptosis. Apoptosis is a cellular process in which the 
members of a family of proteases, the so-called caspases, selectively cleave 
target proteins 67. The cleavage of these proteins results in the breakdown of 
the cell in an ordered manner. Caspases are cysteine proteases, which reside 
in the cytosol as inactive zymogens. After cleavage they become active and 
target aspartate residues on substrate proteins. Caspases are divided into 
initiator and executioner caspases. Initiator caspases such as caspase 8 and 9 
are involved in the first step of activating the caspase cascade 68, 69. They 
cleave proteins involved in the apoptotic machinery such as other pro-
caspases. Executioner caspases such as caspase 3, 6 and 7 are mainly 
involved in the cleavage of cellular substrates. Some of the more profound 
phenotypic changes that occur after caspase activation in apoptotic cells are 
rounding-up of the cell, cell surface expression of PS 70, the formation of plasma 
  
14 
membrane blebs, shedding of plasma membrane derived apoptotic bodies and 
micro-particles 71, 72, chromatin condensation, fragmentation of DNA 73 and in 
the final phase cellular shrinkage 74. Caspases are activated either via the 
extrinsic or the intrinsic pathway. 
 
Extrinsic pathway of caspase activation 
Activation via the extrinsic pathway occurs via death receptors present on the 
plasma membrane such as the CD95/Fas-receptor, TRAIL-receptor and the 
tumor necrosis factor-α (TNF-α)-receptor 75. An extensively studied activation 
pathway is the CD95/Fas-receptor-induced apoptotic pathway. The Fas-
receptor is present in the plasma membrane as a monomer when this pathway 
has not been activated. However, after binding of Fas-ligand, the monomers co-
localize and form trimers in a structure called the death inducing signaling 
complex (DISC) 76, 77. The cytoplasmic domain of each receptor in the DISC is 
linked via an adaptor protein (FADD) to a pro-caspase 8 molecule. Receptor 
trimerization brings each pro-caspase 8 present in the DISC in close proximity 
to another pro-caspase 8. The presence of two pro-caspase 8 molecules in 
close proximity to each other results in a catalytic process in which each pro-
caspase 8 cleaves its neighbor 78. Activated caspase 8 cleaves pro-caspase 3 
and/or the protein BID into truncated BID. Truncated BID is involved in the 
release of pro-apoptotic proteins from the inner membrane of the mitochondrion 
79. Activated caspase 3 cleaves the various proteins present in the cell that 
contain a caspase 3 cleavage site. 
 
Intrinsic pathway of caspase activation 
The intrinsic pathway is not activated via ligation of plasma membrane-located 
death receptors but via activation of intracellular pathways. A diverse array of 
stimuli like ultraviolet radiation, chemical agents such as etoposide, cisplatin or 
staurosporin and deprivation of serum factors can cause the activation of these 
pathways 80-82. The various pathways converge on the release of proteins 
present in the inner membrane of the mitochondrion into the cytosol 83. The 
proteins which are released include cytochrome C, apoptosis inducing factor 
(AIF), endonuclease G and Smac/DIABLO. The next step is the formation of a 
complex known as the apoptosome from released cytochrome C, apoptotic 
protease activating factor (Apaf-1), pro-caspase 9 and ATP 84, 85. The 
apoptosome activates the caspase cascade by converting inactive pro-caspase 
9 into active caspase 9. One of the first targets of caspase 9 in the caspase 
cascade is pro-caspase 3 which is converted into its activated state. The 
intrinsic and the extrinsic pathway cleave identical substrates after activation of 
caspase 3. 
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Figure 2, The caspase activation cascade. Simplified model depicting the activation of 
the intrinsic and extrinsic caspase activation pathway. (Further details are given in the 
text). 
 
Phospholipid translocation across the plasma membrane 
The interior of a cell is separated from the extracellular environment via the 
plasma membrane. The plasma membrane consists of a phospholipid bilayer 
which is composed of charged aminophospholipids, like phosphatidylserine 
(PS) and phosphatidylethanolamine (PE) which reside predominantly in the 
inner leaflet and uncharged phospholipids, such as phosphatidylcholine (PC) 
and sphingomyelin (SM), which reside in the inner and outer leaflet 86. 
In normal healthy cells this asymmetry of the plasma membrane is actively 
maintained, however asymmetry is lost in activated platelets adhered to 
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collagen or in dying cells 87, 88. Loss of membrane asymmetry on the cell surface 
is however not restricted to dying cells. In recent years several studies have 
appeared that report on cell surface expression of PS in specific circumstances 
independent of cell death. PS expression occurs on the cell surface of 
leukocytes for instance on monocytes that differentiate into macrophages, 
positively selected B-cells and on a subpopulation of T-lymphocytes. Cell 
surface expression of PS can also occur after stimulation of monocytes and 
activated neutrophils with the β-galactoside-binding proteins galectin-1, -2 and -
4 89-93. Also, myoblasts fusing into myotubes transiently express PS on their cell 
surface 94. 
It is thought that the active maintenance of phospholipid asymmetry is carried 
out by peripheral membrane proteins or by proteins present in the plasma 
membrane. Several transporters have been postulated to exist 95. Inward 
translocation is mediated by the aminophospholipid translocase. Translocation 
is ATP-dependent and is specific for PS and with a lesser efficiency also for PE. 
A rise in intracellular calcium concentration causes inactivation of the inward 
translocation process. A possible candidate for the aminophospholipid 
translocase, a P-type ATPase, has been identified by Tang and co-workers 96. 
Scramblase is an anti-porter that translocates phospholipids from the outer 
leaflet to the inner leaflet and vice versa. Translocation occurs in an ATP-
independent manner and activation occurs after a sufficient rise in intracellular 
calcium concentration. Sims and co-workers have proposed that the members 
of a gene family known as the phospholipid scramblase family are responsible 
for bi-directional translocation of phospholipids 97, 98.  Recent results have 
however casted doubt on this claim because a phospholipid scramblase-1 
knockout mouse showed no defects in PS-expression and haemostatic 
processes 99. Outward translocation is carried out by ABC-C1, a member of the 
multi drug resistance (MDR) protein family 100, 101. 
The intracellular pathways involved in the inactivation of the aminophospholipid 
translocase and the activation of scramblase and ABC-C1 are mostly unknown. 
PS expression on the cell surface of dying cells is dependent on active caspase 
3 during Fas-ligand-induced apoptotic cell death and active cathepsin B during 
TNF-α-induced cell death 102, 103. How caspase 3 and cathepsin B inactivate the 
aminophospholipid translocase and activate scramblase and ABC-C1 is at 
present unclear. It is thought that caspase 3 and cathepsin B act on 
intermediate proteins which are responsible for (in)activation of the 
phosphoplipid translocation proteins. The pathways responsible for cell surface 
expression of PS independent of cell death are currently unknown. 
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Figure 3, Translocation of plasma membrane localized phospholipids. Model 
depicting the translocation of phospholipids between the plasma membrane leaflets 
during cell death. 
 
Phagocytosis of dying cells 
Removal of dying cells occurs mainly by professional phagocytes such as 
macrophages and dendritic cells 66. Other cells such as high endothelial venule 
cells or fibroblasts have also been found to clear dying cells 104, 105. The 
difference between professional phagocytes and other cells appears to be the 
time involved in the clearance process. Professional phagocytes remove dying 
cells much faster than non-professional phagocytes 106. 
Interaction of phagocytes with dying cells occurs in several phases: recognition, 
tethering, phagocytosis and anti-inflammatory responses. Dying cells can be 
recognized by various molecular markers present on the plasma membrane. 
The best-explored molecular marker is PS but other markers such as the 
protein ICAM-3 present on dying leukocytes and an altered sugar composition 
on the plasma membrane have also been found 107-111. Dying cells release a 
chemotactic lipid compound, lyso-phosphatidylcholine, which attracts monocytic 
cells and professional phagocytes 112. Cell surface-expressed PS on dying cells 
has been proposed to be recognized by a putative PS-receptor 113. The identity 
of this PS-receptor has been disputed because a PS-receptor knockout mouse 
showed no defects in vivo or in vitro in the clearance of apoptotic cells 114, 115. In 
addition, the protein identified as the PS-receptor has been located inside the 
nucleus of cells suggesting that the proposed PS-receptor is in fact a nuclear 
protein 116, 117. 
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Recognition of dying cells is further mediated by cell surface adhered PS 
binding opsonins such as milk-fat-globule-E8 (MFG-E8), protein S, annexin A1 
and annexin A2 118-120, 18. Tethering of the phagocyte to the dying cell is followed 
by phagocytosis via a macropinocytic-like mechanism 121. Phagocytes that have 
engulfed dying cells further prevent an immune response by releasing the anti-
inflammatory mediators TGF-beta, platelet activating factor (PAF) and 
prostaglandine E2 (PGE2) 122. 
 
Imaging of cell death in vivo with annexin A5 
Fadok et al. showed in their 1992 paper that dying cells express PS on the 
plasma membrane 107. An in vitro assay was developed by Reutelingsperger et 
al. in 1994 to measure PS-expression by staining dying cells with annexin A5 
123, 124. The following years many in vitro studies were published that showed the 
usefulness of this assay. These studies focused on PS expression of dying cells 
in in vitro systems. In 1997 van den Eijnde et al. published a study which 
showed that dying cells could be visualized in the complex environment of 
developing tissue 125. They visualized dying cells by injecting a mouse embryo 
with biotin labeled annexin A5. The mouse was subsequently sacrificed and 
embedded in paraffin. Peroxidase conjugated streptavidin was then used to 
show binding of biotin-labeled annexin A5 to PS-expressing cells in coupes of 
the interdigiting tissue in the mouse paw. Visualization of dying cells in tissue 
was further demonstrated by Dumont et al. in a mouse model of the ischemic 
heart 126. The coronary artery of the mouse was ligated for 30 minutes and 
reperfusion was allowed for 90 minutes. Biotin-labeled annexin A5 was injected 
into the circulation before sacrifice and paraffin embedding of the heart. Annexin 
A5 localization was visualized in a similar manner as van den Eijnde et al. 
These studies showed that dying cells could be visualized in tissues during 
development and during pathological conditions. One drawback of the 
procedure used in these studies was that changes in the occurrence of dying 
cells could not be followed in time because the animals were sacrificed for 
histological analysis. This problem was resolved by using radio nuclide and 
fluorescence-labeled annexin A5. In two studies performed by Blankenberg et 
al. it was shown that technetium-99m (Tc-99m) labeled annexin A5 could be 
used in mice to visualize apoptosis in vivo without sacrificing the target organ 
127, 128. A similar result was obtained by Dumont et al. using fluorescence-
labeled annexin A5 129. 
Imaging studies performed by van den Eijnde et al in 2001 and by Mari et al. in 
2004 showed that fluorescence-labeled annexin A5 was not only localized on 
the plasma membrane of myoblast and apoptotic neural cells but also in the 
cytosol suggesting that annexin A5 was taken up by these cells 94, 130. The 
endocytic pathway responsible for annexin A5 uptake was however not further 
investigated in these studies. 
The annexin A5 methodology was further extended into a clinical setting by 
using Tc-99m-labeled annexin A5. Tc-99m-labeled annexin A5 has been used 
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with success to image apoptosis in a patient with a cardiac tumor 131. Tc-99m-
labeled annexin A5 has also been used in patients with cardiac allograft 
rejection, myocardial infarction and unstable atherosclerotic plaques 132-135. One 
of the current drawbacks of the use of annexin A5 in patients is the unfavorable 
biodistribution of annexin A5 136. The clearance process carried out by the liver 
and the kidneys results in a high accumulation of annexin A5 in these organs 
independent of the presence of dying cells. Accumulation of conjugated annexin 
A5 leads consequently to a high back ground signal in these organs. 
 
A short overview of endocytic pathways 
Our investigations into the consequences of annexin A5 binding to cell surface 
expressed PS revealed that annexin A5 is internalized by cells that express PS 
on the cell surface. Here we describe the endocytic pathways that are used by 
cells to internalize proteins, present in the extracellular environment, into the 
cytosol. 
The exchange of large molecules between the extracellular environment and 
the interior of a cell is accomplished via the process of endocytosis. 
Endocytosis is characterized by uptake of extracellular material in membrane 
encapsulated vesicles. There are several endocytic pathways present in cells, 
the clathrin-mediated pathway, the caveolar pathway and the macropinocytic 
pathway 137. Internalization via the clathrin-mediated pathway occurs at coated 
pits; these are specialized sites on the plasma membrane responsible for the 
internalization of cell surface receptors and ion-channels. Internalization is 
initiated after crystallization of the clathrin/AP-2 complex at the cytosolic side of 
the plasma membrane. The plasma membrane is curved inward by the two-
dimensional crystal lattice of the clathrin/AP-2 complex. Membrane curvature 
leads to the formation of a spherical vesicle which is fissured from the plasma 
membrane in a GTP-dependent manner by dynamin proteins. 
Another internalization pathway is mediated by lipid micro-domains on the cell 
surface known as caveolae 138. Caveolae are a subset of discrete membrane 
compartments known as lipid rafts. They consist of plasma membrane 
invaginations comprised of polymerized caveolin-1 proteins, cholesterol and 
glycosphingolipids. Fission of vesicles from the plasma membrane is mediated 
by dynamin proteins. Caveolae have been found to play a role in the 
internalization of plasma membrane proteins such as tissue factor 139. 
Macropinocytosis is involved in the non-specific internalization of solutes 140. 
Internalized vesicles, macropinosomes, are formed at sites of membrane 
ruffling. They contain an actin coat and they are heterogeneous in size. 
Macropinocytosis occurs constitutively in macrophages, dendritic cells and in 
some types of tumor cells 141-143. 
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Aim of this thesis 
The aim of this thesis was to examine the effect of PS binding and two-
dimensional crystal formation of annexin A5 on the dynamics of the PS-
expressing cell surface. In chapter 2 of this thesis we describe the concept that 
annexin A5 can be used as a tool to detect cell surface expression of PS. We 
define the cell physiological processes under which cell surface expression of 
PS occurs and we describe the experimental conditions necessary for annexin 
A5-PS binding. In chapter 3 we examined cell surface changes of apoptotic 
Jurkat cells. We found that annexin A5 is able to inhibit the formation of PS-
expressing microparticles generated by apoptotic Jurkat cells. We further found 
that annexin A5 is internalized by PS-expressing apoptotic Jurkat cells and 
viable HeLa tumor cells. We found that internalization of annexin A5 on cell 
surface expressed PS is dependent on trimer formation of annexin A5. In 
chapter 4 we examined whether annexin A5 induces internalization of cell 
surface expressed tissue factor. And in chapter 5 we examined the plasma 
membrane changes that occur during etoposide-induced apoptosis in THP-1 
monocytic cells using annexin A5 to detect the onset of apoptosis. We found 
that annexin A5-binding monocytic cells have lost the capacity to roll and 
adhere to P-selectin exposing platelets. We discovered that this is the result of 
plasma membrane changes occurring at the onset of the apoptotic process. 
This thesis ends with a general discussion in which the relevance of the results 
presented in this thesis are discussed in relation to current knowledge. 
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Summary 
One of the hallmarks of cell death is cell surface expression of 
phosphatidylserine. Expression of phosphatidylserine at the cell surface can be 
measured in vitro with the phosphatidylserine-binding protein annexin A5 
conjugated to fluorochromes. This measurement can be made by flow 
cytometry or by confocal scanning-laser microscopy. The annexin A5 affinity 
assay comprises the incubation of cells stimulated to execute cell death with 
fluorescence-labeled annexin A5 and propidium iodide. Living cells are annexin 
A5 negative and propidium iodide negative, cells in the early phases of cell 
death are annexin A5 positive and propidium iodide negative, and secondary 
necrotic cells are annexin A5 positive and propidium iodide positive. The entire 
procedure takes about 30 minutes for flow cytometry and 45 minutes for 
confocal scanning-laser microscopy. Various precautions and considerations 
are discussed further in the protocol described here. 
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Introduction 
Of the various methods available for detecting dying cells, the measurement of 
phosphatidylserine (PS) expressed at the cell surface is the most rapid and 
convenient. PS is an aminophospholipid that resides in the inner leaflet of the 
plasma membrane of living cells. In dying cells, PS is actively externalized to 
the plasma membrane’s outer leaflet that faces the extracellular environment 1. 
PS serves as an ‘eat me’ signal recognized by phagocytes via a putative PS 
receptor and via a plethora of proteins that opsonize the PS-expressing 
membrane surface 2. PS expressed at the cell surface can be measured with 
the PS-binding protein annexin A5 conjugated to fluorochromes by flow 
cytometry and by confocal scanning-laser microscopy (CSLM). In conjunction 
with the permeability probe propidium iodide, a distinction can be made 
between dying cells with intact plasma membrane integrity and (secondary) 
necrotic cells 3, 4. 
 
Cell death 
The multicellular organism strives to maintain a balanced number of cells by 
regulating cell creation versus cell demise. The latter occurs mainly through 
developmental cell death. Developmental cell death is part of a set of various 
types of cell death that can become manifest in morphologically and 
biochemically distinct forms depending on the cell type and the trigger inducing 
cell death. These types of cell death include apoptosis, anoikis, necrosis, mitotic 
catastrophe, autophagy, excitotoxicity, wallerian degeneration and 
cornification5. Apoptosis, the most prominent form of cell death, is defined by 
changes occurring at the morphological level, such as rounding-up of the cell, 
retraction of pseudopodes, reduction in cellular volume (pyknosis), 
condensation of chromatin, fragmentation of the nucleus (karyorhexis), little or 
no ultrastructural modification of cytoplasmic organelles, plasma membrane 
blebbing and the maintenance of an intact plasma membrane until late phases 
of the process. Anoikis is defined as apoptosis induced by loss of attachment to 
the substrate or to other cells. Necrosis is also defined by alterations at the 
morphological level, such as cytoplasmic swelling, mechanical rupture of the 
plasma membrane, dilation of cytoplasmic organelles and moderate chromatin 
condensation. Cell death by mitotic catastrophe occurs during or shortly after a 
dysregulated or failed mitosis. This form of cell death is characterized by the 
presence of micronuclei (chromosomes that have not been distributed evenly 
between two daughter cells) or ‘multi-nuclei’ (more than one nucleus). 
Autophagy is defined as a form of cell death without chromatin condensation. 
Cell death is accompanied by morphological changes in the cytoplasm, such as 
the appearance of two-membraned autophagic vacuoles that contain 
degenerating organelles or cytosol. The other forms of cell death, excitotoxicity 
and wallerian degeneration, which occur in the nervous system, and the 
cornification of epidermal cells, have been incompletely characterized. The 
various types of cell death are not strictly defined by biochemical analysis alone. 
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For example, DNA laddering is a frequent phenomenon during apoptosis but 
does not occur with all forms of apoptosis. Furthermore, caspase activation is 
one of the hallmarks of apoptotic cell death, but inhibition of the caspase 
cascade does not always prevent cell death. However, it has become evident 
that most forms of cell death share the phenomenon of cell surface expression 
of PS 6. Externalization of PS is an early event in the sequence of steps leading 
to cell death; it starts well before the plasma membrane integrity is 
compromised 7. PS is therefore a likely ligand for target-specific measurement 
of cell death. Green fluorescent annexin A5 is the most widely used target-
specific probe for measurement of cell death. The annexin A5 affinity assay 
discriminates among living cells, cells in the early phase of cell death and 
(secondary) necrotic cells that have a compromised cell membrane 3, 4. 
 
Cell death–independent PS externalization 
The molecular pathways involved in the externalization of PS to the cell surface 
are mostly unknown. Expression of PS relies on activated caspase 3 in CD95-
induced apoptotic cell death, whereas cathepsin B activity is necessary for PS 
expression in tumor necrosis factor-α–induced caspase-independent cell - 
death 8, 9. Several studies have shown that pathways exist that cause cell 
surface expression of PS by living cells in specific conditions. Cell surface 
expression of PS has been noted in many types of leukocytes, such as 
monocytes differentiating into macrophages, a subpopulation of T lymphocytes 
and positively selected B lymphocytes 10–12. Furthermore, some cells can be 
stimulated to express PS independently of cell death, such as stimulation of 
monocytes and formyl-Met-Leu-Phe–activated neutrophils with the β-
galactoside-binding protein galectin-1 13. Also, myoblasts fusing into myotubes 
transiently express PS at their cell surface 14. Hence, targeting PS to measure 
cell death would produce false-positive results in those cases. 
 
The annexin A5 affinity assay to measure cell death 
Annexin A5 is a member of the annexin protein family that binds in a calcium-
dependent way to PS-containing membranes 15. The tertiary structure of 
annexin A5 consists of a core of four domains arranged in a cyclic array, giving 
the molecule a slightly curved shape with a convex face and a concave face. 
The calcium- and PS binding sites are located at the convex, membrane-facing 
curve of the protein. Annexin A5 binds extrinsically and reversibly to PS-
expressing membranes with a K d in the nanomolar range. The annexin A5 
affinity assay is based on the incubation of unfixed cells with annexin A5 
conjugated to a detectable flag such as a fluorochrome and with the vital dye 
propidium iodide. Other vital dyes such as 7-amino-actinomycin D can be used 
instead of propidium iodide. The annexin A5 affinity assay measures the 
fraction of cells that are annexin A5 negative and propidium iodide negative; 
annexin A5 positive and propidium iodide negative; or annexin A5 positive and 
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propidium iodide positive. The assay requires that the following conditions be 
met or avoided: 
1. The incubation mixture should contain Ca2+ ions at a concentration between 
0.5 mmol L-1 and 3 mmol L-1. The preferred concentration for Ca2+ is 1 mmol L-1. 
The Ca2+ concentration should not exceed 5 mmol L-1, because annexin A5 
increases affinity toward other phospholipid species such as 
phosphatidylcholine with increasing Ca2+ concentration. Bound annexin A5 
dissociates from the PS-containing membrane if the Ca2+ ions are removed, 
such as by chelation with EDTA. 
2. The mixture should not be buffered on the basis of phosphates. 
Recommended buffers are HEPES and Tris-hydroxymethylaminoethane. The 
assay can also be done in cell culture medium. Measurements in RPMI 1640 
medium are not recommended because of the relatively high concentration of 
phosphate and low concentration of Ca2+. Media that have been found to satisfy 
the PS-binding conditions of annexin A5 include DMEM and Medium 199. 
3. Flow cytometry of adherent cell lines requires the detachment of cells from 
the culture flask or plate. However, trypsinization of adherent cells has been 
found to induce binding of annexin A5, leading to false-positive results. False-
positive results are prevented when cells are detached by scraping after 
annexin A5–propidium iodide incubation 16. Flow cytometry of the resulting cell 
suspension produces an annexin A5–versus–propidium iodide dot plot with 
living cells (annexin A5 negative and propidium iodide negative), living cells with 
a compromised membrane due to scraping (annexin A5 negative and propidium 
iodide positive), dying cells (annexin A5 positive and propidium iodide negative) 
and secondary necrotic cells (annexin A5 positive and propidium iodide 
positive).  
4. Cells should not be fixed before incubation with annexin A5. Fixation with 
paraformaldehyde induces cell surface expression of PS on living cells, 
resulting in false-positive results. If fixation is required, the cells should be 
incubated with annexin A5 first, then be washed with Ca2+-containing buffer and 
subsequently be fixed in a buffer containing 1–3 mmol L-1 Ca2+ ions.  
5. The calcium-dependent PS-binding properties of annexin A5 are lost below a 
pH of 5.2 and with prolonged incubation above a temperature of 42°C.  
6. Fluorescence-labeled annexin A5 should be stored refrigerated at 2–8°C. It 
should not be stored frozen because it will lose biological activity because of 
dimerization.   
 
Measurement of cell death: a comparison of various assays  
The progress of cell death is often assessed by measurement of caspase 
activation and with the TUNEL (terminal deoxynucleotidyl transferase–mediated 
dUTP nick end-labeling) method. Caspases are proteolytic enzymes that exist 
as inactive zymogens in living cells. Induction of apoptosis leads to the 
activation of caspases by proteolytic cleavage of the inactive zymogen into the 
active, cleaved caspase. Activated caspases can be detected by Western blot 
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with antibodies to cleaved caspase fragments and by flow cytometry using 
fluorescent probes 17, 18. Caspases are activated early in the apoptotic process 
before PS expression, so with this method it is possible to detect cells at the 
onset of apoptosis 8. Assessment of caspase activity consumes more time than 
the annexin A5 affinity assay does. Furthermore, caspase activation does not 
occur in all types of cell death. The TUNEL method consists of the visualization 
of fragmented DNA in the nucleus 19. Fragmentation of DNA occurs in the late 
stages of cell death, after PS expression has started 7. This method consists of 
many steps and is consequently time consuming. Furthermore, degradation of 
DNA does not occur in all types of cell death; thus, assessment of cell death 
with TUNEL may lead to false-negative results. Annexin A5 can be conjugated 
with various fluorochromes, such as fluorescein isothiocyanate, FP488, Alexa 
Fluor dyes, phycoerythrin and carbocyanines. This offers versatility for use with 
other fluorescence-conjugated probes, such as in multicolor flow cytometry. As 
annexin A5 detects various forms of cell death, it is recommended that more 
than one assay be used for studying a particular type of cell death. For 
example, caspase activity, DNA fragmentation and cell-morphological 
characteristics can be assessed in addition to the annexin A5 affinity assay.  
 
Materials 
Reagents 
\Antibody to Fas (the receptor for Fas ligand; clone 7C11; Immunotech) or other 
cell death–inducing agents 
\Binding buffer (see Reagent setup) 
\Fixation buffer (see Reagent setup) 
\Green fluorescent annexin A5 (Nexins Research BV, Invitrogen, Interchim) 
\Propidium iodide (Invitrogen) 
\Ionomycin (Sigma) 
\Paraformaldehyde (Merck) 
\Bovine serum albumin (Sigma) 
\Nail polish 
\Glycerol 
 
Equipment 
\Flow cytometer 
\Confocal scanning-laser microscope 
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Reagent setup  
10x \concentrated binding buffer:  
The 10x \concentrated binding buffer is 250 mmol L-1 HEPES plus NaOH, pH 
7.4, 1.4 mol L-1 NaCl and 10 mmol L-1 CaCl2. Dilute 10x \concentrated binding 
buffer 1:10 in water for use, to 25 mmol L-1 HEPES plus NaOH, pH 7.4, 140 
mmol L-1 NaCl and 1 mmol L-1 CaCl2. Store binding buffer at 2–8°C. The binding 
buffer will be stable for 6 months if sterilized by filtration through a filter with a 
pore size of 2 µm.  
4% paraformaldehyde fixation buffer: 
To prepare 100 mL of 4% (wt/vol) paraformaldehyde fixation buffer, dissolve 4 g 
paraformaldehyde in 80 mL distilled water. Add some drops of 5 mol L-1 NaOH 
and heat the solution to facilitate dissolution of the paraformaldehyde. When the 
paraformaldehyde is dissolved, add 10 mL of 10x \concentrated binding buffer. 
Adjust the pH to 7.4 with 1 mol L-1 HCl. Add distilled water to 100 mL.  
▲ Critical: Paraformaldehyde solution must be freshly prepared on the day of 
use. 
 
Protocol 
As described above, there are two main options used for measuring cell death 
by annexin A5. To measure PS expression by flow cytometry, follow option A; to 
visualize cell surface expression of PS by CSLM, follow option B. 
 
(A) Measurement of PS expression by flow cytometry 
(i) Suspend cells at a density of 1 × 106 cells per mL in the appropriate medium 
at 37°C and induce cell death with a selected agent; for example, with 200 ng 
mL-1 antibody to Fas. As a positive control for cell surface expression of PS, 
incubate 1 × 106 cells per mL with 5 µmol L-1 ionomycin in binding buffer for 10 
min. Ionomycin is a calcium ionophore that causes an increase in the 
intracellular calcium concentration and subsequent expression of PS at the cell 
surface.  
(ii) Obtain samples of 5 × 104 cells (50 µL) at predetermined time points and 
dilute each sample with 450 µL binding buffer. Add 250 ng mL-1 green 
fluorescent annexin A5 and 250 ng mL-1 propidium iodide and incubate the 
mixture in the dark for 5–15 min at 20–25°C (ambient temperature) or on ice, 
depending on the research question.  
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? Troubleshooting 
(iii) Do two-color flow cytometry. Binding of green fluorescent annexin A5 at the 
cell surface and propidium iodide uptake can be measured without the 
necessity of including a washing step. If washing steps are required, the wash 
buffer should contain 1–3 mmol L-1 CaCl2. The presence of Ca
2+ ions ensures 
that the cell-bound annexin A5 remains bound during the washing procedure. 
The final washing step should also include 250 ng mL-1 propidium iodide.  
(iv) Analyze the flow cytometry data ‘offline’. Set the quadrants in the green 
fluorescent annexin A5–versus–propidium iodide dot plot of the untreated 
control cells. Living cells, annexin A5–binding, and propidium iodide–positive 
cells are found in the bottom left quadrant, bottom right and top right quadrant, 
respectively (Fig. 1). 
 
 
 
Figure 1, Flow cytometry of apoptotic Jurkat cells with annexin A5–FP488 and 
propidium iodide. Forward- and side-scatter plots of untreated control Jurkat cells (a) 
and Jurkat cells treated with antibody to Fas (e). (b–d, f–h) Annexin A5–FP488 and 
propidium iodide dot plots of living and early apoptotic cells (grey; b, f), dot plots of dead 
cells with compromised integrity of the plasma membrane (black; c, g) and dot plots of 
apoptotic bodies (light grey; d, h). Bottom left quadrants, living cells; bottom right 
quadrants, cells in the early phase of cell death; top right quadrants, cells in the phase of 
cell death with leaky plasma membrane. 
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(B) Visualization of cell surface expression of PS by CSLM 
(i) Suspend cells at a density of 1 x106 cells per mL in the appropriate medium 
at 37°C and induce cell death with a selected agent; for example, with 200 ng 
mL-1 antibody to Fas. 
(ii) Add a sample of 5 x\105 cells per mL to a microcentrifuge tube and spin cells 
for 2 min at 200g in a microcentrifuge. 
(iii) Remove the supernatant and resuspend cells in 500 µL binding buffer. Add 
250 ng mL-1 of fluorescence labeled annexin A5 and 250 ng mL-1 propidium 
iodide and incubate for 5–15 min at ambient temperature or on ice, depending 
on the research question. 
? Troubleshooting 
(iv) Spin cells in a microcentrifuge for 2 min at 200g and resuspend the cells in 
500 µL binding buffer. 
(v) Spin cells in a microcentrifuge for 2 min at 200g. Remove the supernatant, 
resuspend cells in 500 µL of 4% paraformaldehyde in binding buffer (the fixation 
buffer should be freshly prepared) and incubate for 15 min at ambient 
temperature. 
▲ Critical step 
Cell samples should not be fixed with paraformaldehyde before incubation with 
fluorescence-labeled annexin A5 because this produces false-positive results. 
The paraformaldehyde buffer solution should contain CaCl2 at a concentration 
ranging from 1 mmol L-1 to 3 mmol L-1. 
(vi) Spin cells in a microcentrifuge for 2 min at 200g. Remove the supernatant 
and resuspend cells in 500 µL binding buffer supplemented with 1% (wt/vol) 
bovine serum albumin. 
(vii) Spin cells in a microcentrifuge for 2 min at 200g. Resuspend cells in 10 µL 
binding buffer and 30 µL glycerol. 
(viii) Place 15 µL of the cell suspension on a glass slide and place a glass 
coverslip over the cell suspension. Seal the glass coverslip onto the glass slide 
with nail polish and analyze the cells by CLSM using wavelength excitation at 
488 nm for green fluorescent annexin A5 and 568 nm for propidium iodide. 
 
Troubleshooting 
Steps (A) (ii) and (B) (iii) 
Annexin A5 is an ‘adopted name’ according to a consensus taxonomy that 
accommodates the growing list of members of the annexin family. Its former 
name was annexin V. That name is still used in many publications and by 
vendors of fluorescence labeled annexin A5 kits. Some vendors do not describe 
the contents of fluorescence-labeled annexin A5 in the kit. In those cases, the 
dilution recommended by the protocol included with the kit should be used or 
the optimal dilution should be determined by construction of a dose-response 
relationship. 
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█ Timing 
The total amount of time necessary for completing the flow cytometry procedure 
is about 30 min. The procedure comprises 10 min for ionomycine treatment, 15 
min for the annexin A5–propidium iodide staining and 5 min for flow cytometry 
measurement. 
 The total amount of time necessary for completion of the CSLM procedure is 
about 45 min. The procedure comprises a microcentrifuge step of 2 min, 
annexin A5–propidium iodide staining for 15 min, a microcentrifuge step of 2 
min in which the supernatant with annexin A5–propidium iodide is removed, a 
microcentrifuge step of 2 min in which the cells are washed, a fixation step of 15 
min, a microcentrifuge step of 2 min in which the supernatant with 
paraformaldehyde solution is removed, a microcentrifuge step of 2 min in which 
the cells are washed, and a short step in which the cells are suspended in 
glycerol and binding buffer and subsequently mounted on a glass slide. 
 
 
 
Figure 2, CSLM analysis of apoptotic Jurkat cells with annexin A5–FP488 and 
propidium iodide. Images are of an early apoptotic Jurkat cell (a) and a late apoptotic 
Jurkat cell with a leaky plasma membrane (b). Original magnification, ×63. 
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Anticipated results 
We measured cell death of the T lymphoma Jurkat cell line using the annexin 
A5 affinity assay (Fig. 1). We incubated Jurkat cells in the absence (Fig. 1a–d) 
and presence (Fig. 1e–h) of 200 ng mL-1 antibody to Fas at 37ºC, labeled the 
cells with annexin A5–FP488 and propidium iodide and then analyzed the cells. 
We obtained forward-scatter and side-scatter plots of untreated control cells 
(Fig. 1a) and cells treated with antibody to Fas (Fig. 1e). We also obtained 
annexin A5–FP488–versus–propidium iodide dot plots of living and early 
apoptotic cells (Fig. 1b,f, red), dot plots of dead cells with compromised integrity 
of the plasma membrane (Fig. 1c,g, blue) and dot plots of apoptotic bodies (Fig. 
1d,h, green). Living cells, cells in the early phase of cell death and cells in the 
phase of cell death with leaky plasma membrane are in the bottom left, bottom 
right and top right quadrants, respectively.  
We also measured cell death with the annexin A5 affinity assay by CSLM (Fig. 
2). We incubated Jurkat cells for 4h with 200 ng mL-1 antibody to Fas at 37ºC, 
labeled the cells with annexin A5–FP488 (green) and propidium iodide (red) and 
then analyzed them by CSLM.  We obtained images of an early apoptotic Jurkat 
cell (Fig. 2a) and a late apoptotic Jurkat cell with a leaky plasma membrane 
(Fig. 2b). 
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Chapter 3 
 
Trimerization of annexin A5 on plasma membrane expressed 
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Summary 
Expression of phosphatidylserine (PS) at the cell surface is part of the 
membrane dynamics of apoptosis. Expressed phosphatidylserine functions as 
an "eat me" flag toward phagocytes. Here, we report that expressed PS forms 
part of a hitherto undescribed endocytic pathway. Annexin A5 is a protein which 
binds in a calcium dependent manner to PS-expressing membranes. Membrane 
binding is followed by trimeriztion of annexin A5 molecules and the subsequent 
formation of a trimer based two-dimensional crystal lattice. PS-binding of 
annexin A5 at the PS-expressing cell surface prevents apoptotic body formation 
without interfering with the progression of apoptosis as demonstrated by 
activation of caspase-3 and DNA fragmentation. Internalization of annexin A5 
was observed with apoptotic Jurkat lymphoma cells and viable Hela cells. The 
two-dimensional crystal lattice bends the membrane patch nanomechanically 
into the cell and elicits budding and endocytic vesicle formation. Internalization 
was not observed with a mutant annexin A5 which was able to bind PS but 
unable to form a membrane bound trimer. In addition annexin A1, which binds 
to PS without forming a two-dimensional crystal lattice, does not induce the 
formation of endocytic vesicles. This novel pinocytic pathway differs from 
macropinocytosis, caveolar or clathrin-mediated endocytosis. In conclusion, this 
novel endocytic pathway depends on the presence of cell surface expressed PS 
and on the capacity of annexin A5 to form a trimer based two-dimensional 
crystal lattice.  
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Introduction 
Cells which are unwanted, damaged or senescent turn into apoptosis, an 
abundant form of cell death 1. Apoptotic cells are removed from tissues by 
phagocytes in a silent and non-provocative manner 2. Removal of apoptotic 
cells plays an essential role in development and tissue homeostasis of the 
multicellular organism. Apoptosis is further found in tissues which are damaged 
by pathological insults such as heart tissue in ischemia/reperfusion injury 
caused by myocardial infarction. The phenotypic changes observed in apoptotic 
cells are caused by proteolytic enzymes known as caspases 3. Caspases are 
activated shortly after ligation of death receptors present on the cells surface. 
Activation of one of the caspases, caspase 3, causes various changes on the 
cell surface such as the appearance of a variety of "eat me" signals and the 
generation of microparticles 4-7. Phosphatidylserine (PS) is the most well-
explored "eat me" signal. It is expressed at the cell surface very early after the 
onset of apoptosis, regardless of the cell type and the apoptosis inducing 
trigger8. Clearance of the apoptotic cell is carried out by phagocytic cells that 
recognize cell surface expressed PS by a recently described PS-receptor 9. 
Annexin A5 is a member of an evolutionary conserved multigene family of 
calcium and phospholipid binding proteins 10. It binds calcium-dependently, with 
high affinity and in a reversible manner to PS-expressing membranes 11. 
Membrane binding is followed by the formation of annexin A5 trimers which 
subsequently associate, via protein-protein interactions, to form larger 
structures such as dimers of trimers and trimers of trimers 12, 13. The association 
of trimers leads to the formation of a two-dimensional crystal lattice which is 
characterized by P3 or P6 symmetry 14. This phenomenon was explored using 
model membranes but is also believed to occur on the apoptotic cell surface. In 
a recent study Gidon-Jeangirard et al. observed that in the presence of annexin 
A5 the generation of microparticles by apoptotic cells was inhibited 15. They 
proposed that the inhibition of microparticle formation was caused by the two-
dimensional crystal lattice formed by annexin A5. 
Annexin A5 is used to detect cell surface expression of PS on apoptotic cells 16. 
In this study we examined the involvement of the formation of annexin A5 
trimers and the subsequent two-dimensional crystal lattice on the membrane 
dynamics of the PS-expressing cell surface. We demonstrate that the inhibition 
of microparticle formation by annexin A5 is not dependent on the capacity of 
annexin A5 to form a two-dimensional crystal lattice. We observed that annexin 
A5 was internalized by cells that expressed PS on the cell surface. Endocytosis 
of annexin A5 by PS-expressing cells was dependent on the capacity of 
annexin A5 to form trimers. 
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Materials and methods 
Chemicals 
Human apo-transferrin was purchased from Sigma and Tris-(hydroxymethyl) 
Aminomethane (Tris) was obtained from Acros Organics. 
 
Cell culture 
The T-lymphoma cell line Jurkat (ATCC) was routinely grown in RPMI 1640 
medium (Gibco BRL), containing 100 units mL-1 penicillin, 0.1 mg mL-1 
streptomycin (Gibco BRL), and 10% Fetal Bovine Serum (PAA Laboratories 
GmbH). HeLa cells (ATCC), were maintained in Modified Eagle Medium (MEM) 
with Earl's salts (Gibco BRL) supplemented with 10% Fetal Bovine Serum, 1% 
non-essential amino acids, 100 units mL-1 penicillin, 0.1 mg mL-1 streptomycin 
(Gibco BRL). The cells were grown at 37°C in a humidified atmosphere and 5% 
CO2. 
 
Molecular modeling and site directed mutagenesis 
The Internal Coordinate Mechanics (ICM) software package form Molsoft (San 
Diego, USA) was used to create a three-dimensional model of a membrane 
bound annexin A5 trimer. The structure of the annexin A5 trimer was based on 
data published by Sopkova et al. 17. The model was subsequently used to 
determine the location of putative amino acids involved in protein-protein 
interactions responsible for trimer formation. Site-directed mutagenesis was 
performed on annexin A5 cDNA using the Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA) according to the manufacturer's instructions 
generating the annexin A5 mutant 2D1-6 with amino acid substitutions R63A, 
K70A, K101A, E138A, D139G and N160A. 
 
Cloning, expression, purification and labeling of annexin A5, 2D1-6, M1234 
and annexin A1 
cDNA encoding for the annexin A5 mutant M1234 (E72D, D144N, E228A and 
D303N) having four defective calcium binding sites was kindly provided by Prof. 
Dr. F. Russo-Marie (BIONEXIS-Pharmaceuticals). M1234 cDNA was recloned 
to remove the 5’ base pairs responsible for the 3 extra N-terminal amino acids 
after expression 18.  
Annexin A5 and M1234 and 2D1-6 cDNA's were cloned into the bacterial 
expression vector pET-5a (Novagen). Proteins were expressed in Escherichia 
coli and purified to homogeneity as assessed by silver stained SDS-PAGE and 
Western blotting. Annexin A5, M1234 and 2D1-6 were labeled with Alexa568-
succinimidylester according to the manufacturers protocol (Molecular Probes). 
The proteins which were labeled with 1:1 stoichiometry were purified from the 
mixtures by MonoQ chromatography with Äcta Explorer (Amersham-
Pharmacia). Annexin A1 was kindly provided by Dr. E. Solito (London, UK). 
Annexin A1 was labeled with Alexa568-succinimidylester according to the 
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manufacturers protocol (Molecular Probes). The PS-binding capacity of annexin 
A1-Alexa568 was verified by ellipsometry. 
 
Plasmid and transfection 
The plasmid caveolin-1-GFP was a kind gift of Dr. D. Mundy (University of 
Texas, Southwestern Medical Center, Dallas) and is described in 19. The 
plasmid was transfected in HeLa cells with the transfection agent Fugene 6 
(Roche Applied science). 
 
Confocal scanning laser microscopy (CSLM) 
Jurkat cells (2 x 106 cells mL-1) were stimulated with anti-Fas (200 ng mL-1) in 
the presence of annexin A5-oregon green (20 µg mL-1), annexin A1-Alexa568 
(20 µg mL-1) and cytoskeletal agents if indicated. After 3h the cells were 
pelleted (2 min 1000g), washed with EDTA-buffer (140 mmol L-1 NaCl, 25 mmol 
L-1 Hepes, 5 mmol L-1 EDTA, pH 7.4) and resuspended in Ca2+-buffer (10 mmol 
L-1 Hepes, 150 mmol L-1 NaCl, 5 mmol L-1 KCl, 1 mmol L-1 MgCl2, 2.5 mmol L
-1 
CaCl2, pH 7.4). The cells were stained with annexin A5-alexa568 (250 ng mL
-1) 
for 5 min, washed and resuspended in Ca2+-buffer containing 4% 
paraformaldehyde. After a fixation period of 10 min, the cells were stained with 
Phalloidin-TRITC according to the manufacturers’ protocol (Invitrogen). HeLa 
cells were seeded on glass cover slips and left to adhere in culture medium. 
After 24h one or a combination of the fluorescent labeled proteins was added in 
a concentration of 100 nmol L-1. HeLa cells were incubated at 37°C and 5% 
CO2 for 3h. The HeLa cells were washed sequentially with phosphate buffered 
saline (PBS), EDTA-buffer and PBS. The cells were then fixed for 15 min in 
Ca2+-buffer containing 4% paraformaldehyde (pH 8.0) and washed three times 
for 20 min in PBS. The fixed Jurkat or HeLa cells were mounted in 90% glycerol 
in 0.02 mol L-1 Tris-HCl pH 8.0 with addition of 2% 1,4-diazobicyclo-[2,2,2]-
octane (Merck). Slides were examined with a confocal scanning laser 
microscope (Bio-Rad) equipped with a Crypton/Argon mixed gas laser (Ion 
Laser Technology). Images were recorded and analyzed with NIH image, 
ImageJ and Adobe Photoshop. Variations on this standard protocol were used 
to study the internalization of annexin A5-Alexa568 (100 nmol L-1), M1234-
Alexa568 (100 nmol L-1), annexin A1-Alexa568 (100 nmol L-1), 2D1-6-Alexa568 
(100 nmol L-1), transferrin-Oregon Green488 (100 nmol L-1) and Oregon Green 
labeled Tris (20 µmol L-1) with the succinimidylester group inactivated. 
 
Two-dimensional crystallization and electron crystallography 
The experimental conditions and procedure for growing annexin A5 2D-crystals 
onto functionalized monolayer are described in details in 20. In our case 17 µL of 
60 µg emL-1 annexin A5 and of the 2D1-6 solutions in 10mmol L-1 HEPES, pH 
7.4, containing 150 mmol L-1 NaCl, 2 mmol L-1 CaCl2 and 3 mmol L
-1 NaN3 were 
deposited in a Teflon well of 4 mm diameter and 1 mm depth. 0.6 µL lipid 
solution containing 150 mmol L-1 DOPS / 450 mmol L-1 DOPC in chloroform / n-
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hexane (1:1 w/w) was deposited on the top of the solution to form the 
functionalized lipid monolayer. The 2D protein-lipid domains were formed onto 
the lipid/buffer interface after overnight incubation at 21oC in a humid chamber. 
The two-dimensional protein-lipid domains were transferred onto carbon-coated 
electron microscopy grids and negatively stained with 1% Uranyl acetate 
solution as described previously (20, 21). The grids were observed in a JEOL 
2010 transmission electron microscope operated at 200kV, equipped with a 
LaB6 and 2x2k CCD ultra-scan digital camera (Gatan, Inc) with 15 micron / 
pixel resolution. All data were collected as 2048x2048 digital images at a total 
magnification of 38700 times and low-electron dose conditions (< 1500 electron 
/ nm2). The Digital Micrograph Images were converted in MRC format using the 
EMAN software (http://ncmi.bcm.tmc.edu/~stevel/EMAN/doc/) and further 
analyzed with the CRISP 2D crystallography software (http://www.calidris-
em.com). 
 
Analysis of microparticle formation 
Jurkat cells were washed and resuspended at 106 cells per mL in DMEM (Gibco 
BRL). Apoptosis was induced with anti-Fas (200 ng mL-1) in the presence of 
annexin A5, 2D1-6, M1234, annexin A1 or ROCK-1 inhibitor Y-27632. The 
course of apoptosis was determined by flow cytometry using the annexin A5-
FITC staining protocol (Nexins). Microparticle formation was quantified with flow 
cytometry and subsequent off-line calculation of the percentage of events with 
reduced forward and sideward scatter. Off-line analysis of the flow cytometer 
files was performed with WinMDI 2.8 (free share software designed by Joseph 
Trotter). 
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Results 
Phosphatidylserine binding of Annexin A5 inhibits microparticle formation 
In order to asses the effect of two-dimensional lattice formation of annexin A5 
on plasma membrane dynamics we examined the interaction of annexin A5 with 
the cell surface of apoptotic cells. The progress of the apoptotic program in anti-
Fas stimulated Jurkat cells was analyzed in the presence and absence of 
annexin A5. Exposure of PS on the plasma membrane of apoptotic cells is 
accompanied with the generation of PS-exposing microparticles. We observed 
that co-incubation of Jurkat cells with anti-Fas and annexin A5 changed the 
apoptotic membrane dynamics such that microparticle formation was inhibited 
(fig. 1a). 
We examined whether the capacity of annexin A5 to bind PS was necessary for 
the inhibition of microparticle formation by incubating anti-Fas treated Jurkat 
cells with the annexin A5 mutant M1234. M1234 lacks calcium binding sites and 
is consequently unable to bind to PS. Flow cytometric analysis revealed that 
M1234 did not inhibit the formation of microparticles indicating that the PS 
binding property of annexin A5 is necessary in inhibition of microparticle 
formation (not shown). 
Microparticles are formed after phosphorylation of the myosin light chain by 
caspase activated ROCK-1. In our model system inhibition of ROCK-1 with Y-
27632 inhibits microparticle formation indicating that ROCK-1 activation is 
necessary for the formation of microparticles. We examined the possibility that 
annexin A5 binding to apoptotic Jurkat cells inhibits the cleavage and the 
subsequent activation of ROCK-1. Co-incubation of Jurkat cells with anti-Fas 
and annexin A5 showed that parts of the apoptotic program such as caspase-3 
activation (fig. 1b), DNA fragmentation (fig. 1c) and ROCK-1 activation (fig. 1d) 
were not altered when compared to control cells. This result indicates that 
annexin A5 does not inhibit the cleavage and activation of ROCK-1. 
Annexin A5 forms a two-dimensional lattice on a PS-expressing membrane 
surface while annexin A1 does not form a two-dimensional lattice. We examined 
the possibility that two-dimensional lattice formation of annexin A5 is necessary 
for inhibition of microparticle formation. Co-incubation of Jurkat cells with anti-
Fas and annexin A1 showed that annexin A1 inhibits, dose-dependently, the 
formation of microparticles suggesting that two-dimensional lattice formation of 
annexin A5 is not necessary for inhibition of microparticle formation (fig 1e). 
Taken together these results indicate that inhibition of microparticle formation by 
annexin A5 is dependent on the capacity of annexin A5 to bind calcium-
dependently to PS. 
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Figure 1, Annexin A5 inhibits the formation of apoptotic bodies. Microparticle 
formation of Jurkat cells after treatment with 200 ng mL-1 anti-Fas antibody for 3h in the 
absence and presence of 10 µg mL-1 annexin A5 and M1234 (fig.1a). Time course of 
caspase-3 activation of anti-Fas-treated Jurkat cells in the absence (open circles) and 
presence (filled circles) of 10 µg mL-1 annexin A5 (fig. 1b). DNA laddering after 3h of 
anti-Fas treatment in the absence and presence of 10 µg mL-1 annexin A5 (fig. 1c). Time 
course of ROCK-1 cleavage of Jurkat cells treated with anti-Fas antibody in the presence 
and absence of 10 µg mL-1 annexin A5 (fig 1d). Dose-response of microparticle 
formation of Jurkat cells after treatment with 200 ng mL-1 anti-Fas antibody for 3h in the 
presence of 1, 10 and 50 µg mL-1 annexin A1 (fig. 1e). 
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Figure 2, Annexin A5 is internalized via a PS-dependent pathway. CSLM of anti-Fas-
treated Jurkat cells incubated for 3h with 20 µg mL-1 annexin A5-oregon green (fig. 2a) 
and counter stained for 5 min. with annexin A5-alexa568 (fig 2b). Figure 2c shows the 
composition of figure 2a and 2b. CSLM of HeLa cells incubated with 100 nmol L-1 of 
annexin A5-alexa568 (Fig. 2e) and counter stained with phalloidin-oregon green (fig. 2d). 
Fig. 2f shows the composition of figure 2d and 2e. 
 
 
 
Figure 3, Annexin A5-containing vesicles in apoptotic Jurkat cells are coated with 
actin. CSLM of anti-Fas-treated Jurkat cells in the presence annexin A5-Oregon Green 
and stained for F-actin with TRITC-labeled phalloidin (fig. 3a). CSLM of anti-Fas-treated 
Jurkat cells in the presence (fig. 3b) and absence (fig. 3c) of cold annexin A5. CSLM of 
Jurkat cell treated with 0.5 µmol L-1 of latrunculin B (fig. 3d). 
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Figure 4, Annexin A5 is not internalized by HeLa cells via a known endocytic 
pathway. CSLM of HeLa cell which has internalized the macropinocytic probe Oregon 
Green (4a; green) and annexin A5-Alexa568 (4b; red). Fig. 4c was obtained after 
merging of 4a and 4b.  HeLa cells were transfected with caveolin 1-enhanced green 
fluorescent protein and 24h later incubated with 100 nmol L-1 annexin A5-Alexa568. 
HeLa cell containing caveolin 1-enhanced green fluorescent protein (4d; green) and 
annexin A5-alexa568 (4e; red). Fig. 4f was obtained after merging of 4d and 4e.  CSLM 
of HeLa cells that have internalized transferrin-Oregon Green488 (4g; green) and 
annexin A5 alexa568 (4h; red). Fig. 4i shows the composition of figure 4g and 4h. 
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Internalization of annexin A5 occurs via a PS-dependent endocytic 
pathway 
Data from in vivo imaging of apoptotic cells with annexin A5 have suggested 
that annexin A5 not only binds to the PS exposing cell surface but also that 
annexin A5 internalizes into the apoptotic cell (Ph. D. thesis, H. Kenis). This 
observation prompted us to investigate this phenomenon closer in an in vitro 
system. Jurkat cells were induced to undergo apoptosis with anti-Fas treatment 
and incubated with annexin A5-oregon green. CSLM analysis revealed the 
presence of intracellular vesicles containing annexin A5-oregon green (Fig. 2 a). 
We demonstrated that these vesicular structures are endocytic vesicles and not 
part of an open cannicular system by i) washing the cells with EDTA and ii) 
incubating them shortly with annexin A5-alexa568 prior to CSLM analysis (fig. 
2b). This procedure neither removed annexin A5-oregon green from the 
vesicular structure nor resulted in co-localization of annexin A5-oregon green 
and annexin A5-alexa568. The latter bound to the plasma membrane only. 
Internalization of annexin A5 was not observed in healthy Jurkat cells nor did 
internalization occur in apoptotic Jurkat cells with mutant M1234-alexa568. 
Execution of apoptosis results in the surface expression of PS, which is a 
requirement for internalization of annexin A5 in apoptotic Jurkat T-lymphocytes. 
In order to determine whether apoptosis is a necessity for internalization we 
incubated HeLa cells that were not submitted to apoptotic stimuli with annexin 
A5-Alexa568. HeLa cells were incubated for 3 hours with annexin A5-alexa568. 
Fig. 2d shows a CSLM image of a HeLa cell stained with the actin dye 
phalloidin-oregon green. CSLM analysis further demonstrated the presence of 
intracellular vesicles of various sizes containing annexin A5 (Fig. 2e). Annexin 
A5 inside the vesicles could not be removed by treatment with EDTA-buffer. 
The internalization was not coupled to the execution of the apoptotic program 
because i) zVAD-fmk, a caspase inhibitor, did not inhibit annexin A5 
internalization and ii) the cells with internalized annexin A5 were viable (not 
shown). Internalization of M1234-alexa568 in HeLa cells was not observed. We 
conclude from these results that annexin A5 is taken up in endocytic vesicles in 
apoptotic Jurkat and HeLa tumor cells via a PS-dependent mechanism. 
 
Annexin A5 is internalized via a novel endocytic pathway 
Cells can internalize proteins from the extracellular environment via several 
endocytic pathways. We examined the possibility that annexin A5 is internalized 
via one of these pathways. The size distribution of the annexin A5 endocytic 
vesicles suggests that the uptake is a macropinocytic process. This process is 
dependent on actin dynamics which is involved in ruffling of the cell surface 22. 
Jurkat cells were co-incubated for three hours with anti-Fas and annexin A5-
Oregon Green. Staining of F-actin with Phalloidin-Texas Red revealed the 
presence of an actin coat around the annexin A5-containing vesicles, 
suggesting the involvement of the actin cytoskeleton (Fig. 3a). When anti-Fas 
treated Jurkat cells were incubated with annexin A5 we observed intracellular 
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vesicles coated with actin (Fig 3b). These vesicles were not observed in the 
absence of annexin A5 (fig. 3c). Treatment of Jurkat cells with latrunculin B, an 
actin-depolimerizing agent, did not prevent the uptake of annexin A5 in 
endocytic vesicles indicating that annexin A5 is not internalized via 
macropinocytosis (Fig. 3d). The macropinocytic pathway is further characterized 
by internalization of solutes in a non-specific manner. HeLa cells were co-
incubated with annexin A5-alexa568 and the macropinocytic probe oregon-
green. CSLM analysis showed the presence of two distinct populations of 
vesicles, one containing annexin A5-alexa568 (fig. 4a) and the second Oregon 
Green (fig. 4b). These two populations of intracellular vesicles did not co-
localize with each other (Fig. 4c). Co-incubation of HeLa cells for 3 hours with 
M1234-alexa568 and Oregon Green showed that only Oregon Green was 
internalized but not M1234 demonstrating that annexin A5 is internalized via a 
PS-dependent pathway distinct from macropinocytosis (not shown). 
We investigated whether annexin A5 is internalized via the clathrin-mediated 
endocytic pathway. The endocytic vesicles generated by the clathrin-mediated 
pathway have a uniform size. The reported diameter of clathrin coated vesicles 
is 100 nm 23. The annexin A5-containing vesicles are heterogeneous is size. In 
both apoptotic Jurkat and living HeLa cells the annexin A5-containing vesicles 
have a diameter ranging from 0.2 to 1.0 µm. We co-incubated HeLa cells with 
transferrin-oregon green, a protein internalized via the clathrin mediated 
pathway, and annexin A5-alexa568. Fig. 4d shows a CSLM image of a HeLa 
cell which has internalized transferrin-oregon green and annexin A5-alexa568 
(fig. 4e). Fig. 4f demonstrates the difference in diameter between vesicles 
containing transferrin and annexin A5. CSLM analysis shows that transferrin-
containing vesicles do not co-localize with annexin A5-containing vesicles. 
We next examined a possible involvement of the caveolar endocytic pathway in 
the internalization of annexin A5. Lymphocytes do not express the membrane 
protein caveolin-1 which is part of the molecular machinery of the caveolar 
endocytic pathway indicating that annexin A5 is not internalized in Jurkat 
lymphoma cells via caveolae. We examined the possibility that annexin A5 is 
internalized by HeLa cells via the caveolar endocytic pathway. HeLa cells were 
transfected with EGFP-caveolin-1-expressing plasmid and incubated 24h later 
with annexin A5-alexa568. Fig. 4g shows a CSLM image of a HeLa cell 
expressing EGFP-caveolin-1 which has internalized annexin A5-alexa568 (fig. 
4h). CSLM analysis showed that EGFP-caveolin-1 did not co-localize with 
annexin A5-alexa568-containing intracellular vesicles (fig. 4i) demonstrating that 
annexin A5 is not internalized via caveolae.  
Taken together our data show that annexin A5 is internalized through a process 
that differs mechanistically from macropinocytosis, clathrin-mediated and 
caveolar endocytosis. 
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Trimer formation of annexin A5 is essential for endocytosis 
The tertiary structure of annexin A5 shows that its phospholipid binding side has 
a convex shape. When bound to the membrane annexin A5 forms trimers of 
which each monomer retains the convex shape at its phospholipid binding side. 
We hypothesized that the trimers bend the membrane and provide the driving 
force for membrane movement. In order to test this hypothesis we created the 
annexin A5 mutant 2D1-6 which was able to bind PS but unable to form a 
trimer. Several criteria were used to establish that 2D1-6 had lost its ability to 
form trimers but not its capacity to bind calcium-dependently to PS. We 
examined the possibility that the introduction of mutations in the annexin A5 
protein results in a change in structure. Analysis of the secondary structure of 
2D1-6 by circular dichroism showed however no significant change when 
compared to annexin A5 (not shown). We next examined the ability of 2D1-6 to 
bind calcium-dependently to PS. Elipsometric measurements demonstrated that 
the calcium-dependent binding properties of 2D1-6 were virtually the same as 
annexin A5 (not shown). This was further corroborated by CSLM analysis which 
showed that 2D1-6-alexa568 (fig. 5a) was able to bind to the surface of 
ionomycin and calcium-treated HeLa cells. Fig. 5b shows binding of annexin-
alexa568 to ionomycin and calcium-treated HeLa cells. We finally examined the 
ability of 2D1-6 to form a membrane-bound two-dimensional crystal lattice. 
Fourier analysis of the electron diffraction pattern generated by electron-
irradiation of membrane bound annexin A5 showed a characteristic hexagonal 
pattern, previously reported for two-dimensional crystals of annexin A5 obtained 
in similar conditions (Fig. 5c) 12, 13. Further analysis showed the typical trimeric 
organization of annexin A5. Fourier analysis did not reveal a hexagonal pattern 
and trimeric organization for membrane-bound 2D1-6. This result indicates that 
according to Fourier analysis 2D1-6 does not form an observable trimer-based 
two-dimensional crystal lattice.  
Our results so far suggested that the two-dimensional crystal lattice is not 
responsible for the inhibition of microparticle formation. We confirmed this by 
demonstrating that 2D1-6 can inhibit the formation of apoptotic Jurkat cell 
derived microparticles (not shown). To investigate the involvement of the two-
dimensional crystal lattice in the endocytosis of annexin A5, we incubated HeLa 
cells for 3h with 2D1-6-alexa568. Fig. 5d shows HeLa cells stained with the 
actin dye phalloidin-oregon green. CSLM analysis of these HeLa cells revealed 
that endocytic vesicles containing 2D1-6-alexa568 were absent (Fig. 5e). We 
obtained a similar result for apoptotic Jurkat cells incubated with 2D1-6-
alexa568 (not shown). These experiments indicate that trimerization of annexin 
A5 and the subsequent two-dimensional crystal formation is necessary for the 
endocytosis of annexin A5 by cells that express PS on the cell surface. This 
conclusion was supported by experiments in which apoptotic Jurkat and viable 
HeLa cells were incubated with annexin A1-alexa568. Fig. 6a shows a CSLM 
image of apoptotic Jurkat cells with intracellular vesicles containing annexin A5-
alexa568. Annexin A1-alexa568 was able to bind the PS-expressing cell surface 
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of the apoptotic Jurkat cell however intracellular vesicles containing annexin A1-
alexa 568 were absent (fig. 6b). HeLa cells contained intracellular vesicles 
containing annexin A5-alexa568 (fig. 6d) but intracellular vesicles containing 
annexin A1-alexa568 were not observed (fig. 6e). Interestingly, when apoptotic 
Jurkat cells were co-incubated with annexin A5-oregon green and annexin A1-
alexa568 we observed intracellular vesicles containing both annexin A5 and 
annexin A1 suggesting that annexin A5 is able to internalize PS-binding 
proteins (fig 6c). We observed a less pronounced co-localization of annexin A5 
and annexin A1 when HeLa cells were co-incubated with annexin A5-oregon 
green and annexin A1-alexa668 (fig 6f). In some vesicles we did not observe 
co-localization of annexin A5 and annexin A1 while in other vesicles annexin A1 
was marginally present.  
 
 
             
 
 
 
Figure 5, Endocytosis of annexin A5 is dependent on annexin A5 trimer formation. 
HeLa cells treated with ionomycin and stained with annexin A5-alexa568 (fig 5a; red) 
and 2D1-6-alexa568 (fig 5b; red). Two-dimensional density projection map of annexin A5 
two-dimensional crystals at 2.0 nm resolution (fig. 5c). The protein density is in white, P3 
symmetry has been imposed. The unite cell dimensions (from hole to hole) are a = b = 
11nm, γ = 120o, phase residual 11.6o. HeLa cell stained with phalloidin-oregon green (fig 
5d; green) and incubated for 3h with 100 nmol L-1 of 2D1-6-alexa568 (fig 5e; red). Fig. 5f 
shows the composition of figure 5d and 5e. 
C 
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Discussion 
In this study we examined the effect of the formation of trimers and two-
dimensional crystallization of annexin A5 on the membrane dynamics of the PS-
expressing cell surface. Apoptotic cell death causes various changes on the cell 
surface such as the externalization of PS to the outer membrane leaflet and the 
shedding of receptor bearing microparticles 4-7. Recently, it was reported that 
annexin A5 inhibits microparticle formation by the application of a physical 
constraint, i.e. a two-dimensional crystal lattice, on the plasma membrane 15. 
We confirmed that annexin A5 inhibits, dose-dependently, the formation of 
microparticles. Inhibition of microparticle formation was however not caused by 
the two-dimensional crystal lattice because 2D-1-6 and annexin A1 (which are 
able to bind PS but which are unable to form a two-dimensional crystal lattice) 
were able to inhibit microparticle formation. 
During our study into the inhibition of microparticle formation by annexin A5 we 
observed that annexin A5 was internalized by apoptotic Jurkat cells and viable 
HeLa cells. Our investigations into this phenomenon revealed the existence of 
an endocytic pathway that involves annexin A5 and cell surface-expressed PS. 
We found that annexin A5 was not internalized via one of the known endocytic 
pathways. The endocytic vesicles containing annexin A5 were heterogeneous in 
size which suggested that annexin A5 was internalized via macropinocytosis. 
The formation of macropinosomes is dependent on the activity of actin 
polymerisation process. However, the experiments with the actin disruption 
agent latrunculatin B showed that annexin A5 is internalized by apoptotic Jurkat 
cells when the actin polymerisation process is inhibited. Furthermore, in HeLa 
cells annexin A5 did not co-localize with endocytic vesicles containing a 
macropinocytosis marker. We further demonstrated that annexin A5 was neither 
internalized by the caveolar nor by the clathrin-mediated endocytic pathway. 
In order to obtain more insight into the mechanism that is responsible for 
endocytosis of annexin A5 we focused our investigation on the two-dimensional 
crystallization property of annexin A5. Oling et al. have demonstrated that 
annexin A5 molecules do not significantly change conformation after binding to 
a PS-expressing membrane surface 13. This means that annexin A5 molecules 
in solution and the molecules bound to PS have a convex shape at the 
phospholipid binding side. This further indicates that the various domains have 
an unequal distance to the phospholipid membrane surface 13. Domain III is the 
most distant from the membrane surface and domain II the closest. All four 
domains contain a calcium-binding motif making it possible that membrane-
bound annexin A5 influences the PS-expressing membrane surface to adopt a 
shape that is complementary to the convex shape of the annexin A5 molecule. 
We hypothesized that the convex shape of annexin A5 monomers, that is 
retained when annexin A5 is assembled into a two-dimensional crystal lattice, 
imposes a curvature to the PS-expressing plasma membrane on which annexin 
A5 is bound. Membrane curvature is subsequently followed by the formation of 
a spherical endocytic vesicle. To test this hypothesis we generated an annexin 
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A5 mutant that was able to bind to PS but unable to form a trimer. Sopkova et 
al. have published data on the crystal form-1 from which it is possible to deduce 
the presence of two different trimer conformations (Fig. 7a) 17. In the first trimer 
conformation the annexin A5 molecules are oriented in such a manner that 
domain two of each individual annexin A5 molecule is present inside and 
domain three on the outside of the trimer (Fig 7b). In the second trimer 
conformation the annexin A5 molecules are oriented in a reverse manner. Each 
annexin A5 molecule in this trimer is oriented with domain three present in the 
inside and domain two on the outside (Fig. 7c). Both trimers are not formed with 
equal likelihood because the formation of the first trimer (Fig. 7b) is 
energetically more favourable than the second trimer (Fig. 7c).  
The annexin A5 mutant, 2D1-6, which was unable to form trimers was created 
by introduction of  mutations at the putative amino acid locations that were 
predicted to be involved in the formation of the first trimer structure (Fig. 7b). 
These amino acids were identified after modelling the trimer structure using 
protein-protein docking protocols in the Molsoft software package. To test 
whether the 2D1-6 mutant had lost its capacity to induce internalization, we 
incubated apoptotic Jurkat lymphoma and viable HeLa tumor cells with 
fluorescently labeled 2D1-6. We demonstrated with CSLM analysis that there 
were no endocytic vesicles containing 2D1-6 present inside these cells. We 
concluded from this result that trimerization and the formation of a two-
dimensional crystal lattice were necessary for endocytosis of annexin A5. This 
conclusion was supported by experiments which showed that fluorescently 
labeled annexin A1 was not internalized by apoptotic Jurkat and viable HeLa 
cells.  
Studies with artificial membranes have revealed that annexin A5 trimers can be 
packed in such a way that four two-dimensional crystal types are formed. These 
types include the crystal form-1, the crystal form-2 and the crystals 
characterized by P6 (fig. 7d) and P3 (fig. 7e) symmetries 14. The crystal 
characterized by P6 symmetry is commonly found on artificial PS-expressing 
membranes while the other three types are rarely found. The crystal lattice 
characterized by P6 symmetry is found on membrane surfaces which consists 
of 25 mol% PS and 75 mol% PC 14. The crystal characterized by P3 symmetry 
is found on membranes with a higher PS content. It is not known whether or not 
the P6 or P3 crystal lattices are formed on biological membranes. This might 
depend on the manner in which PS is distributed on the plasma membrane. PS 
might be localized in micro-domains or it is homogeneously distributed. It is 
possible that both P6 and P3 crystal types are formed on the plasma membrane 
when there are micro-domains present which have a high PS content. 
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Figure 6, Annexin A5 and not annexin A1 opens a novel portal of cell entry. a–c, 
CSLM analyses of Jurkat cells that were co-incubated with anti-Fas and annexin A5-
Alexa568 (fig. 6a), annexin A1-Alexa568 (fig. 6b), or the combination of annexin A5-
Oregon Green and annexin A1-Alexa568 (fig. 6c). CSLM analyses of living HeLa cells 
that were incubated with annexin A5-Alexa568 (fig. 6d), annexin A1-Alexa568 (fig. 6e) or 
the combination of annexin A5-Oregon Green and annexin A1-Alexa568 (fig. 6f). 
 
We hypothesize that the two-dimensional crystal lattice causes bending of the 
membrane which is followed by the formation of an endocytic vesicle via an 
unknown mechanism. The vesicles that are present in the cytosol of both 
apoptotic Jurkat and HeLa tumor cells are heterogeneous in size. The following 
two hypothetical mechanisms may account for the heterogeneous vesicle size: 
(i) PS-containing micro-domains on the cell surface can have various diameters. 
Large and small endocytic vesicles are then created as annexin A5 crystallizes 
on PS-containing micro-domains that have respectively large and small 
diameters. (ii) Annexin A5 trimers can associate to form P6 or P3 crystals on 
the cell surface, however the extent as to which these crystal types induce 
membrane curvature is different. The difference in membrane curvature may 
subsequently lead to large and small endocytic vesicles. 
The relevance of the annexin A5 endocytic pathway during apoptosis is 
debatable. Why should a cell determined to die be capable of activating 
endocytic pathways? Recent articles have reported on cell surface expression 
of PS on viable cells independent of cell death. PS expression has been found 
to occur on living leukocytes for example on positively selected B-cells, a 
subpopulation of T-lymphocytes and on monocytes that differentiate into 
macrophages 24-26. Furthermore monocytes and activated neutrophils express 
PS independent of cell death after stimulation with dimeric galectin-1 27. These 
findings suggest that it is possible that the annexin A5-PS endocytic pathway is 
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not only active on dying cells but also on living cells. In this paper we 
demonstrated the likelihood of this possibility by showing that the annexin A5 
endocytic pathway exists in living HeLa cells. 
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Figure 7, Trimer structure and two-dimensional lattice formation of annexin A5. 
Figure 7a shows the crystal form-1 of annexin A5. This crystal lattice consists of two 
types of trimer structures shown in fig. 7b and 7c. Figure 7b’ shows the location of the 
mutations that were introduced into annexin A5 to obtain 2D1-6. Trimers can associate 
into a crystal lattice characterized by P6 symmetry (fig. 7d) or P3 symmetry (fig. 7e). 
Figures 7a-c are adapted from Sopkova et al. (J Mol Biol., 1993) and figures 7d-e are 
adapted from Oling et al. (J Struct Biol., 2001). 
 
 
 
 
 
 
 
 
 
  
66 
References 
1. Leist, M., and Jaattela, M. Nat. Rev. Mol. Cell Biol. 2: 589-598 (2001). 
2. Savill, J., Dransfield, I., Gregory, C. & Haslett, C. A blast from the past: 
clearance of apoptotic cells regulates immune responses. Nat. Rev. 
Immunol. 2: 965–975 (2002). 
3. Hengartner, M. O. Nature 407: 770-776 (2000). 
4. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson 
PM. Exposure of phosphatidylserine on the surface of apoptotic 
lymphocytes triggers specific recognition and removal by macrophages. 
J Immunol. 148: 2207-2216 (1992). 
5. Martin, S.J., Finucane, D.M., Amarante-Mendes, G.P., O’Brien, G.A. & 
Green, D.R. Phosphatidylserine externalization during CD95-induced 
apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. 
J. Biol. Chem. 271: 28753–28756 (1996). 
6. Nusbaum P, Laine C, Bouaouina M, Seveau S, Cramer EM, Masse JM, 
Lesavre P,Halbwachs-Mecarelli L. Distinct signaling pathways are 
involved in leukosialin (CD43) down-regulation, membrane blebbing, 
and phospholipid scrambling during neutrophil apoptosis. J Biol Chem. 
280: 5843-5853 (2005).  
7. Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J. 
Caspase-3-mediated cleavage of ROCK I induces MLC 
phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 3: 
346-352 (2001).  
8. Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., Rader, J. A., van 
Schie, R. C., LaFace, D. M., and Green, D. R. Early redistribution of 
plasma membrane phosphatidylserine is a general feature of apoptosis 
regardless of the initiating stimulus: inhibition by overexpression of Bcl-
2 and Abl. J. Exp. Med. 182: 1545-1556 (1995). 
9. Fadok, V. A., Bratton, D. L., Rose, D. M., Pearson, A., Ezekewitz, R. A., 
and Henson, P. M. Nature 405: 85-90 (2000). 
10. Gerke, V., Creutz, C.E. & Moss, S.E. Annexins: linking Ca2+ signalling 
to membrane Dynamics. Nat. Rev. Mol. Cell Biol. 6: 449–461 (2005). 
11. Andree, H. A., Reutelingsperger, C. P., Hauptmann, R., Hemker, H. C., 
Hermens, W. T., and Willems, G. M. J. Biol. Chem. 265: 4923-4928 
(1990). 
12. Mosser, G., Ravanat, C., Freyssinet, J. M., and Brisson, A. J. Mol. Biol. 
217: 241-245 (1991). 
13. Oling, F., Santos, J. S., Govorukhina, N., Mazeres-Dubut, C., Bergsma-
Schutter, W., Oostergetel, G., Keegstra, W., Lambert, O., Lewit-
Bentley, A., and Brisson, A. J. Structure of membrane-bound annexin 
A5 trimers: a hybrid cryo-EM - X-ray crystallography study. Mol. Biol. 
304: 561-573 (2000). 
 67 
14. Oling F, Bergsma-Schutter W, Brisson A. Trimers, dimers of trimers, 
and trimers of trimers are common building blocks of annexin A5 two-
dimensional crystals. J Struct Biol. 133(1):55-63 (2001). 
15. Gidon-Jeangirard, C., Hugel, B., Holl, V., Toti, F., Laplanche, J. L., 
Meyer, D., and Freyssinet, J. M. J. Immunol. 162: 5712-5718 (1999). 
16. van Engeland, M., Ramaekers, F. C., Schutte, B., and 
Reutelingsperger, C. P. Cytometry 24: 131-139 (1996). 
17. Sopkova J, Renouard M, Lewit-Bentley A. The crystal structure of a 
new high-calcium form of annexin V. J Mol Biol. 5: 234(3):816-25 
(1993). 
18. Mira, J. P., Dubois, T., Oudinet, J. P., Lukowski, S., Russo-Marie, F., 
and Geny, B. J. Biol. Chem. 272: 10474-10482 (1997). 
19. Mundy, D. I., Machleidt, T., Ying, Y. S., Anderson, R. G., and Bloom, G. 
S. J. Cell Sci. 115: 4327-4339 (2002). 
20. Alain Brisson, Wilma Bergsma-Schutter, Frank Oling, Olivier Lambert 
and Ilya Reviakine. Two-dimensional crystallization of proteins on lipid 
monolayers at the air–water interface and transfer to an electron 
microscopy grid. Journal of Crystal Growth 196: 456-470 (1999). 
21. Stoylova SS, Lenting PJ, Kemball-Cook G, Holzenburg A. Electron 
crystallography of human blood coagulation factor VIII bound to 
phospholipid monolayers. J Biol Chem. 274(51): 36573-8 (1999). 
22. Swanson JA, Watts C. Macropinocytosis. Trends Cell Biol. 5(11): 424-8 
(1995). 
23. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 
422(6927): 37-44 (2003). 
24. Dillon, S.R., Constantinescu, A. & Schlissel, M.S. Annexin V binds to 
positively selected B cells. J. Immunol. 166: 58–71 (2001). 
25. Elliott JI, Surprenant A, Marelli-Berg FM, Cooper JC, Cassady-Cain RL, 
Wooding C, Linton K, Alexander DR, Higgins CF. Membrane 
phosphatidylserine distribution as a nonapoptotic signaling mechanism 
in lymphocytes. Nat. Cell Biol. 7: 808–816 (2005). 
26. Callahan MK, Halleck MS, Krahling S, Henderson AJ, Williamson P, 
Schlegel RA.  Phosphatidylserine expression and phagocytosis of 
apoptotic thymocytes during differentiation of monocytic cells. J Leukoc 
Biol. 74(5):846-56 (2003). 
27. Dias-Baruffi M, Zhu H, Cho M, Karmakar S, McEver RP, Cummings 
RD. Dimeric galectin-1 induces surface exposure of phosphatidylserine 
and phagocytic recognition of leukocytes without inducing apoptosis. J 
Biol Chem. 278(42):41282-93 (2003) 
 
 
 
 
  
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 69 
Chapter 4 
 
Annexin A5 induces endocytosis of the complex of tissue factor with 
factor VIIa 
 
Hugo van Genderen, Simone J. Wielders, Theo Lindhout and Chris P.M. 
Reutelingsperger 
 
From the Department of Biochemistry, Cardiovascular Research Institute 
Maastricht, Maastricht, The Netherlands. 
 
Submitted for publication 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
Summary 
Annexin A5 is a protein that binds calcium-dependently to phosphatidylserine 
(PS)-expressing membrane surfaces. Cell surface binding is followed by an 
endocytosis process that is dependent on the capacity of annexin A5 to bind PS 
and to form a two-dimensional crystal lattice. In this study we have investigated 
annexin A5-induced endocytosis of tissue factor (TF) on viable HeLa cells. 
Endocytosis of TF was studied with fluorescently labeled inactivated factor VIIa 
(FVIIai-F) on HeLa cells transfected with TF cDNA. Confocal scanning laser 
microscopy (CSLM) revealed that the TF:FVIIai-F complex was predominantly 
localized on the cell surface at sites of cell-cell contact. Localization at sites of 
cell-cell contact was independent on the cytoplasmic domain of TF. CSLM 
analysis further demonstrated that annexin A5 induces the endocytosis of 
TF:FVIIai-F complex in viable HeLa cells. Annexin A5-induced endocytosis of 
TF:FVIIai-F complex is dependent on the capacity of annexin A5 to bind PS and 
to form a two-dimensional crystal lattice. Endocytosis of TF did however not 
result in a decrease of TF activity suggesting that annexin A5-induced 
endocytosis of TF on viable HeLa cells does not play a role in down regulation 
of coagulation processes initiated by TF-bearing cell surfaces. 
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Introduction 
The annexins are a family of membrane binding proteins that share structural 
properties and biological activities associated with membrane-related 
processes1. One of the members of this family, annexin A5, binds reversibly to 
phosphatidylserine (PS)-expressing membranes with high affinity in a calcium-
dependent manner 2. Binding to PS is accompanied by the formation of a two-
dimensional crystal lattice of annexin A5 molecules through protein-protein 
interactions 3. Recently, we have reported that apoptotic cells internalize 
annexin A5 via a novel route of internalization 4. This endocytic pathway is 
characterized by the generation of endocytic vesicles that are heterogeneous in 
size ranging from 0.2 to 1.0 µm. Endocytosis of annexin A5 is dependent on its 
properties to bind PS and to form a two-dimensional crystal lattice. In addition 
internalization of annexin A5 does not occur via the known endocytic pathways 
such as macropinocytosis and caveolar or clathrin-mediated endocytosis. It is 
hypothesized that the first steps of endocytosis comprise an annexin A5-
induced invagination by annexin A5 as a result of nanomechanical bending of 
the PS-expressing membrane patch 4. Viable cells restrict PS to inner leaflets of 
the plasma membrane by employing aminophospholipid translocases (APLT). 
The APLT P-type ATPase rapidly transports aminophospholipids inwards and in 
an ATP-dependent manner 5. PS is also transported to the exofacial leaflet of 
the plasma membrane via ATP-binding-cassette transporter C1, albeit at low 
rates 6. During apoptosis net aminophosholipid transport shifts towards 
externalization leading to prolonged surface exposure of PS. The shift results 
from the inhibition of APLTs and concomitant activation of scramblases 7. Cell 
surface expressed PS acts as an “eat me” signal towards phagocytes 8. If 
apoptosis occurs in the presence of annexin A5 the PS-expressing membrane 
patches are internalized resulting in inhibition of phagocytosis 9 and down-
regulation of receptors embedded in PS-containing membrane patches 10. The 
latter was shown for tissue factor (TF) and apoptotic THP-1 cells. The relevance 
of this mechanism operating during apoptosis, however, is not well understood. 
Recent studies have shown that viable cells can express PS on the cell surface 
under certain circumstances such as positively selected B-cells, a subset of T-
lymphocytes and neutrophils stimulated with galectin-1 11-13. Living HeLa cells in 
culture express PS and internalize annexin A5 with a mechanism similar to 
annexin A5 internalization by apoptotic cells 4. These findings prompted us to 
examine whether annexin A5 regulates expression of plasma membrane 
receptors of living HeLa cells. Hereto, we have chosen to investigate TF 
internalization by HeLa cells. TF, a 45-kDa type II cytokine receptor that 
possesses one transmembrane domain and a short intracellular COOH-terminal 
tail, initiates the blood coagulation cascade upon complexation with blood 
coagulation factor VIIa in an environment with PS 14, 15. Since, HeLa cells have 
a low expression of TF on the cell surface, functional TF expression was 
provoked by transfection with TF cDNA. TF expression and cell surface location 
was examined with a TF activity assay and by confocal scanning laser 
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microscopy (CSLM). The role of annexin A5 in the internalization of TF was 
examined by using fluorescently-labeled inactivated factor FVIIa. 
 
 
Figure 1, Activity of cell surface expressed tissue factor. The ability of HeLa cells 
and TF-expressing HeLa cells to convert factor X in a factor VIIa-dependent manner was 
measured using a TF activity assay. The TF neutralizing antibody TF5 (10 µg mL-1) and 
annexin A5 (10 µg mL-1) inhibited the ability of TF-expressing HeLa cells to convert FX 
into FXa. 
 
 
Figure 2, FVIIai-F localizes in HeLa cells predominantly at sites of cell-cell contact. 
CSLM images of HeLa cells incubated with 10 nmol L-1 FVIIai-F (green; Fig. 2b) and 
counterstained with phalloidin-texas red (red; Fig. 2a). CSLM images of HeLa cells 
transfected with TF cDNA and subsequently incubated for 1.5h with 10 nmol L-1 FVIIai-F 
(green; Fig. 2e) and counter stained with phalloidin-texas red (red; Fig. 2d). Figure 2c 
and 2f show the composition of 2a-b and 2d-e respectively. 
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Materials and methods 
Cell culture conditions 
HeLa cells, obtained from ATCC, were maintained in modified eagle medium 
(Gibco) supplemented with 10% heat inactivated fetal bovine serum (FBS, PAA 
Laboratories), 1% non-essential amino acids, 100 units mL-1 penicillin and 100 
µg/mL streptomycin (Gibco BRL). The cells were grown at 37°C in a humidified 
atmosphere and 5% CO2. 
 
Cloning, expression, purification and labeling of proteins 
cDNA encoding for the annexin A5 mutant M1234 (E72D, D144N, E228A and 
D303N) having four defective calcium binding sites was kindly provided by Prof. 
Dr. F. Russo-Marie (BIONEXIS-Pharmaceuticals) 16. Annexin A5 and M1234 
cDNAs were cloned into the bacterial expression vector pET-5a (Novagen). 
Proteins were expressed in Escherichia coli and purified to homogeneity as 
assessed by silver-stained SDS-PAGE and Western blotting. Annexin A5, 
M1234 and annexin A1 were labeled with Alexa568-succinimidylester according 
to the manufacturer's protocol (Invitrogen). The labeled proteins with 1:1 
stoichiometry were purified from the mixtures by MonoQ chromatography with 
Äcta Explorer (Amersham Biosciences). Annexin A1 was kindly provided by Dr. 
E. Solito (Imperial College London, London, England). FITC-labeled inactivated 
factor VIIa (FVIIai-F) was prepared as described earlier 10. Briefly, N-α-
[(acetylthio)acetyl]-D-Phe-Pro-Arg-CH2Cl was linked to the active site of factor 
VIIa (Novoseven, NovoNordisk). Then, 1 mg mL-1 acetylthioacetate-Phe-Pro-
Arg-FVIIai was mixed with 0.5 mg mL-1 iodoacetamide-fluorescein, to which 50 
µL of 2 mol L-1 NH2OH was added. This mixture was incubated for 1h, protected 
from light. The fluorescein isothiocyanate-labeled FVIIai was separated from 
free dye on a PD-10 column equilibrated in phosphate buffered saline (PBS). 
 
Plasmids and site directed mutagenesis 
Human Tissue Factor cDNA was obtained from RZPD Deutsches 
Ressourcenzentrum fur Genomforschung (Berlin, Germany). Tissue Factor 
cDNA was amplified by polymerase chain reaction (PCR) from RZPD clone 
IRAUp969D0152D6 from library IRAU MGC Human verified full length cam 
cDNA. TF cDNA containing the full-length coding sequence was amplified by 
PCR using the sense primer 5'-GGTACCATGGAGACCCCTGCCT -3' and the 
anti-sense primer 5'-GGATCCTTATGAAACATTCAGTGG -3'. The sense primer 
contained a Kpn1 restriction site and the anti sense primer contained a BamH1 
restriction site. The PCR fragment was ligated into pGem-t-easy (Promega). 
Tissue factor cDNA was subcloned into pcDNA3.1 (Invitrogen) via restriction 
sites Kpn1 and BamH1 obtaining the plasmid pcDNA3.1-tissue factor. A Site 
Directed Mutagenesis kit (Stratagene) was used to introduce a stop codon in 
the cDNA of TF at amino-acid site 246 by conversion of AGA to TGA obtaining 
the plasmid pcDNA3.1-TF-∆CT. Plasmid DNA sequence was analyzed with 
BigDey Terminator v3.1 cycle sequencing kit from Applied Biosystems. 
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Confocal scanning laser microscopy (CSLM) 
HeLa cells were seeded on glass coverslips and 24 hours later transfected with 
plasmid. The cells were used for experiments 36 hours after transfection. HeLa 
cells were incubated at 37°C and 5% CO2 for 1.5 h with 100 nmol L
-1 annexin 
A5-allexa568, M1234-alexa568, annexin A1-alexa568 and/or 10 nmol L-1 FITC-
labeled inactivated factor VIIa in CaCl2-containing DMEM (Gibco) supplemented 
with 10% FBS. The cells were washed twice with PBS. The cells were then 
fixed for 15 min in 4% paraformaldehyde (pH 8.0) and washed twice with PBS. 
The microtubule disruption agent colchicine (Sigma) was added 1h before 
starting an experiment using a concentration of 10 µg mL-1.  Actin was 
visualized by staining fixed cells with Texas-red or Oregon-green labeled 
phalloidin (Invitrogen) according to the manufacturer’s instructions. After 
phalloidin staining, cells were washed twice with PBS. The coverslips with HeLa 
cells were examined with a confocal scanning laser microscope (Bio-Rad) 
equipped with a Crypton/Argon mixed gas laser (Ion Laser Technology) using 
excitation wavelengths of 488nm for green fluoresce and 568nm red 
fluorescence. Images were recorded and analyzed with Adobe Photoshop 5.0 
and Image J. The fluorescence intensity of membrane bound FVIIai-F was 
measured as the integrated density (ID) using Image J. The ID was defined as 
the sum of grey values present within a region of interest. The average ID was 
measured of eight positions which were randomly selected on the plasma 
membrane of a TF-expressing cell. 
 
Transfection and measurement of tissue factor activity 
HeLa cells were seeded in the wells of a 96 wells plate. Transfection with 
pcDNA3.1-TF and pcDNA3.1-TF-∆CT was carried out 24h after the seeding 
procedure. TF activity was determined 36h after transfection by incubating 
transfected cells with a reaction mixture containing: 100 nmol L-1 factor X, 100 
pmol L-1 factor VIIa, 3 mmol L-1 CaCl2, and 200 µmol L
-1 Pentafluor FXa 
substrate (Pentapharm) as previously described 17.  Fluorescence tracings were 
recorded in a plate spectrofluorometer (Spectramax Gemini XS, Molecular 
Devices, Sunnyvale, CA, USA) at 37°C with an excitation and emission 
wavelength of 350 and 450 nm, respectively. 
 
Statistical analysis 
To determine the statistical significance of means, probability values were 
obtained with a Student T-test. Probability values of < 0.05 were considered 
significant. Error bars indicate standard deviation. 
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Figure 3,  FVIIai-F binds specifically to cell surface expressed tissue factor. TF-
expressing HeLa cells were incubated with 10 nmol L-1 FVIIai-F (fig 3b) and 
subsequently stained with primary polyclonal anti-TF antibody (American diagnostica) 
and secondary alexa568-labeled goat-anti-rabit-antibody (fig. 3a). Fig. 3c shows the 
composition of fig. 3a and 3b. 
 
 
Figure 4, TF is not associated to sites of cell-cell contact via the cytoplasmic 
domain. Hela cells transfected with TF-∆CT (fig. 4a-c) were incubated for 1.5h with 10 
nmol L-1 FVIIai-F and stained with phalloidin-texas red. Fig. 4a shows a CSLM image of 
cells stained with phalloidin-texas red. Fig. 4b shows cells incubated with FVIIai-F. Fig. 
4c was obtained after merging fig. 4a and 4b. Fig. 4d shows the fluorescence intensity of 
membrane bound FVIIai-F expressed as the average integrated density. 
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Figure 5, Annexin A5 induces endocytosis of tissue factor:factor VIIia-F complex in 
HeLa cells. CSLM image of HeLa cell stained with phalloidin-oregon green (green; Fig. 
5a) after incubated for 1.5h with 100 nmol L-1 annexin A5-alexa568 (red; Fig. 5b). Fig. 5c 
was obtained after merging of image 5a and 5b. CSLM image of HeLa cells transfected 
with TF cDNA and incubated for 1.5h with 10 nmol L-1 FVIIai-F (green; Fig. 5d) and 100 
nmol L-1 annexin A5-alexa568 (red; Fig. 5e). Fig. 5f was obtained after merging of image 
5d and 5e. Fig. 5d’, 5e’ and 5f’ are magnifications of fig. 5d, 5e and 5f respectively. 
CSLM images of HeLa cells transfected with TF cDNA were incubated with 10 nmol L-1 
FVIIia-F (green; Fig. 5g) and 100 nmol L-1 annexin A1-alexa568 (red; Fig. 5h). Fig. 5i 
was obtained after merging fig. 5g and 5h. 
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Results 
Localization and activity of cell surface expressed TF 
To examine annexin A5-induced endocytosis of cell surface expressed TF we 
used HeLa cells transiently transfected with TF cDNA as a model system. 
Expression and functionality of cell surface expressed TF was assessed by a 
TF activity assay and confocal scanning laser microscopy (CSLM), respectively. 
Fig. 1 shows that TF cDNA transfected HeLa cells have a 25-fold higher TF 
activity than non-transfected HeLa cells. Factor Xa generation by transfected 
and non-transfected cells could be fully blocked by anti-TF antibody TF5 and by 
annexin A5, indicating that activation of factor X at the cell surface is dependent 
on the presence of both TF and PS. 
We also examined cell surface expression of TF with CSLM. HeLa cells 
transfected with TF cDNA stained on the plasma membrane with primary 
antibody TF5 and secondary phycoerythrin-labeled goat-anti-mouse antibody 
(Dako) indicating the presence of cell surface-located TF and non-transfected 
HeLa cells did not stain for TF (data not shown). Fluorescein-labeled inactivated 
factor VIIa (FVIIai-F) binds stoichiometrically with high affinity to TF. To examine 
cell surface expression of TF in more detail non-transfected HeLa cells were 
incubated for 1.5h with FVIIai-F in a calcium-containing medium. Fig. 2a shows 
a CSLM image of HeLa cells stained with the actin dye phalloidin-texas red. 
Binding of FVIIai-F to non-transfected cells was not observed (Fig. 2b). We next 
studied binding of FVIIai-F to the cell surface of TF cDNA transfected HeLa 
cells. Hereto, transfected cells were incubated with FVIIai-F for 1.5h and then 
analyzed by CSLM. For reference, cells were also stained for actin (Fig. 2d). As 
shown in Fig. 2e, FVIIai-F is localized at a high density in membrane regions 
where cell-cell contact occurred. Non-contact regions showed a much lower 
density. Fig. 2e also shows an intracellular location for FVIIai-F, suggesting that 
the complex of TF:FVIIai-F was partly internalized during the 1.5 hour 
incubation period. The absence of intracellular FVIIai-F in non-transfected cells 
strongly supports the notion that FVIIai-F only internalizes in complex with TF 
(Fig.2b). 
The question of whether internalization of TF:FVIIai-F caused a reduced TF 
activity on the cell surface was addressed by measuring TF-dependent FX 
activation. After 1.5h of treatment with FVIIa, TF activity was not significantly 
decreased (P value > 0.05) when compared to non-treated cells. This finding 
seemingly contrasts the notion that TF is internalized together with FVIIai-F 
(Fig. 2e). A plausible explanation could be a very rapid recycling of internalized 
TF from cytosol to cell surface. 
FVIIa has the capacity to bind via its gamma-carboxyglutamic acid (GLA) 
domain to a PS-containing membrane surface 15. To confirm that FVIIai-F binds 
to cell surface expressed TF and not to PS, we incubated transfected HeLa 
cells for 1.5h with FVIIai-F and subsequently stained these cells with primary 
polyclonal anti-TF antibody (American Diagnostica) and secondary alexa568-
labeled goat-anti-rabbit antibody (Invitrogen). Fig. 3c shows that staining of TF 
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with primary anti-TF antibody and secondary alexa568-labeled antibody (Fig. 
3a) co-localizes with cell surface bound FVIIai-F (Fig. 3b) indicating that FVIIai-
F specifically binds to TF. 
 
Role of the TF cytoplasmic domain in localization of TF at sites of cell-cell 
contact 
We next, examined the role of the TF cytoplasmic domain on the preference of 
TF to associate with sites of cell-cell contact. Staining of HeLa cells with the 
actin dye phalloidin-alexa568 showed that actin is present in high 
concentrations at sites of cell-cell contact (Fig 2d). Because the cytoplasmic 
domain of TF has been reported to interact with the actin cytoskeleton via the 
adaptor protein filamin A 18, we chose to examine whether interaction of the TF 
cytoplasmic domain with the cytoskeleton is involved in the localization of TF at 
sites of cell-cell contact. To this end we transfected HeLa cells with the TF 
deletion mutant TF-∆CT which lacks the cytoplasmic domain. HeLa cells 
transfected with TF-∆CT cDNA were incubated for 1.5h with FVIIai-F. Actin 
stained cells are shown in Fig. 4b as a reference. It is apparent from the CSLM 
recordings that the cellular localization of TF-∆CT is not different from that of 
TF-wild type (cf. Fig. 2e and Fig. 4b). 
The localization of membrane bound FVIIai-F was further analyzed by 
measuring the fluorescent intensity of FVIIai-F as recorded by CSLM. The 
fluorescent intensity was expressed as the average integrated density (ID) of 
the grey values of FVIIai-F. Measurement showed that the ID of FVIIai-F 
present on HeLa cells expressing TF was significantly higher (P value < 0.01) 
on the plasma membrane at sites of cell-cell contact compared to sites that 
were not in contact with other cells (fig. 4d). A similar result was found for HeLa 
cells expressing TF-∆CT. These findings suggest that TF association to sites of 
cell-cell contact is not mediated via the intracellular domain but likely by its 
extracellular domain. In addition, the very same pattern of intracellular 
distribution of FVIIai-F was observed for cells transfected with TF-wild type and 
TF-∆CT, suggesting that endocytosis of TF:FVIIai-F complex is not dependent 
on the cytoplasmic domain of TF. 
 
Annexin A5 induces in viable HeLa cells internalization of TF:FVIIai-F 
Non-transfected viable HeLa cells were incubated for 1.5h with annexin A5-
Alexa568. Fig. 5a shows a CSLM image of a HeLa cell stained with the actin 
dye phalloidin-oregon green. CSLM analysis of this HeLa cell further revealed 
the presence of intracellular vesicles containing annexin A5-alexa568 (fig. 5b). 
When non-transfected HeLa cells were co-incubated with annexin A5-alexa568 
and FVIIai-F we observed intracellular vesicles containing annexin A5-alexa568 
only and no vesicles containing FVIIai-F (not shown). This result indicates that 
annexin A5 does not induce the internalization of FVIIai-F by non-transfected 
HeLa cells.  
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Figure 6, Transport of endocytic vesicles containing both annexin A5 and TF:factor 
VIIai-F complex is microtubule-dependent.  
HeLa cells were pretreated with 10 µmol L-1 colchicine and incubated for 1.5h with 100 
nmol L-1 annexin A5-alexa568. CSLM image of HeLa cell stained with phalloidin-oregon 
green (green; Fig. 6a) and incubated with annexin A5-alexa568 (red; Fig. 6b). Fig. 6c 
was obtained after merging of image 6a and 6b. CSLM image of HeLa cells transfected 
with TF cDNA, pretreated with colchicine and incubated for 1.5h with 10 nmol L-1 FVIIai-
F (green; Fig. 6d) and 100 nmol L-1 annexin A5-alexa568 (red; Fig. 6e). Fig. 6f was 
obtained after merging of image 6d and 6e. Fig. 6d’, 6e’ and 6f’ are magnifications of fig. 
6d, 6e and 6f respectively. 
 
We next determined the effect of extracellular annexin A5 on the internalization 
process of TF bound FVIIai-F in TF cDNA transfected viable HeLa cells. After a 
co-incubation of FVIIai-F and annexin A5-alexa568 for 1.5h, we observed two 
enclosing populations of endocytic vesicles. The first containing only FVIIai-F 
and the second containing both FVIIai-F and annexin A5-Alexa568 (Fig. 5d-f). 
Endocytic vesicles containing only annexin A5-Alexa568 were rarely observed 
in TF-transfected cells. This result prompted us to hypothesize that the 
concomitant endocytosis of annexin A5 together with TF:FVIIai-F complex is 
induced by membrane binding, two-dimensional crystallization of annexin A5 
and by the subsequent endocytic vesicle formation. 
To confirm that internalization of annexin A5 together with TF:FVIIai-F complex 
is dependent on the capacity of annexin A5 to bind PS, we performed the same 
experiment with the non-lipid binding annexin A5 mutant M1234 19. HeLa cells 
transfected with TF cDNA that were incubated with M1234-alexa568 and FVIIai-
 81 
F only comprised vesicles that contained FVIIai-F indicating that the PS binding 
property of annexin A5 is critical for its endocytosis by HeLa cells (not shown). 
Confirming an annexin A5-independent pathway of TF:FVIIai endocytosis. 
Endocytosis of annexin A5 was earlier shown to be dependent on the ability of 
annexin A5 to form a two-dimensional crystal lattice 4. We examined whether 
annexin A5-induced endocytosis of TF is also dependent on the ability of 
annexin A5 to form a membrane bound crystal lattice. Another member of the 
annexin family, annexin A1, binds to PS but does not form a membrane bound 
two-dimensional crystal lattice 18. Transfected HeLa cells expressing TF were 
co-incubated with annexin A1-alexa568 and FVIIai-F. CSLM analysis showed 
cell surface binding of FVIIai-F and intracellular vesicles containing FVIIai-F (fig. 
5g). Fig. 5h shows that intracellular vesicles containing annexin A1-alexa568 
are absent from these cells. This result indicates that not only PS binding but 
also two-dimensional crystal formation of annexin A5 is necessary for annexin 
A5 to internalize together with TF:FVIIai-F complex. 
These results indicate that PS exposition on the plasma membrane of HeLa 
cells is necessary for the internalization of annexin A5. When HeLa cells were 
incubated with annexin A5-alexa 568 we did not detect binding of annexin A5 
on the plasma membrane with CSLM (not shown). This result suggests that 
plasma membrane binding of annexin A5-alexa568 is below the detection limit 
of CSLM measurement. However, annexin A5 does inhibit TF activity of HeLa 
cells, indicating that PS is present on the plasma membrane. 
In order to determine whether transfection of HeLa cells with TF cDNA induces 
exposure of PS on the plasma membrane we incubated transfected cells for 10 
minutes with annexin A5-alexa 568. We did not detect membrane binding of 
annexin A5-alexa568 with CSLM analysis indicating that the transfection 
procedure did not induce upregulation of PS exposition on the cell surface of 
viable HeLa cells (not shown). 
Finally, we studied the effect of annexin A5 on TF internalization by measuring 
the FVIIa-dependent factor X converting activity of TF. TF-expressing HeLa 
cells were incubated for 1.5h with FVIIa in the presence and absence of 
annexin A5. The cells were washed with EDTA-containing buffer before 
measuring TF activity to remove annexin A5 from the cell surface. We did not 
find a significant difference (P value > 0.05) in the factor X-converting activity of 
TF between cells treated with annexin A5 and cells that were not treated with 
annexin A5 (not shown) suggesting that annexin A5-mediated internalized TF, 
like annexin A5-independent internalized TF, is rapidly recycled back to the cell 
surface. 
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Transport of annexin A5-containing vesicles is mediated by microtubuli 
CSLM analysis shows that intracellular vesicles containing both annexin A5 and 
TF:FVIIai-F complex are localized in the perinuclear region (fig. 5f) suggesting 
that these vesicles are subjected to an intracellular transport process. 
Microtubuli have been reported to play a role in the transport of endocytic 
vesicles into the cytosol 20. We, therefore, examined the effect of colchicine, a 
microtubule disruption agent, on the transport process of annexin A5-containing 
vesicles. HeLa cells were pre-treated for 1h with colchicine and subsequently 
incubated for 1.5h with annexin A5-alexa568. Fig. 6a shows a CSLM image of a 
HeLa cell stained with the actin dye phalloidin-oregon green. Colchicine 
treatment caused loss of cellular shape resulting in rounding-up of the cell. 
CSLM analysis of this HeLa cell shows that in colchicine-treated cells, annexin 
A5-alexa568-containing vesicles remain localized nearby the plasma membrane 
indicating that colchicine treatment inhibits the transport of annexin A5-
containing vesicles (fig 6b). We next examined the effect of colchicine treatment 
on the transport of vesicles containing both annexin A5 and FVIIai-F. 
Transfected HeLa cells expressing TF were pre-treated with colchicine and 
subsequently incubated with annexin A5-alexa568 and FVIIai-F. Fig. 6d shows 
that FVIIai-F binds to the cell surface and that FVIIai-F is present in vesicles in 
the cytosol. Fig. 6e further shows that annexin A5-alexa568-containing vesicles 
are present close to the plasma membrane. Vesicles of various sizes containing 
both annexin A5 and TF:FVIIai-F are present in the cytosol near the cell surface 
indicating that the transport process of these vesicles is also inhibited by 
colchicine (fig. 6f). These results demonstrate that vesicles containing annexin 
A5 and vesicles containing both annexin A5 and TF:FVIIai-F complex are 
transported into the cytosol via a microtubule-dependent process. 
 
 
Discussion 
In a previous study we found indications for an annexin A5-mediated 
internalization of TF expressed on apoptotic THP-1 macrophages 10. The 
relevance of the annexin A5-mediated endocytic pathway of TF during 
apoptosis, however, is debatable. Why should a cell determined to die be 
capable of activating endocytic pathways? It should however be emphasized 
that the annexin A5 endocytic pathway in apoptotic cells could be a remnant of 
the pinocytic capabilities of the living cell. In addition, internalization of TF by 
apoptotic cells in contact with the blood circulation could be an important 
mechanism in the down regulation of thrombus formation. To find further 
support for our notions on the role of annexin A5 and PS in endocytosis of 
transmembrane proteins, and in particular that of TF, we performed a study on 
the internalization of TF using living HeLa cells. 
TF-dependent FX activation measurements and CSLM visualization with active 
site labelled FVIIa (FVIIai-F), however, revealed that HeLa cells express only 
small amounts of TF, if any, on their surfaces. Moreover, upon incubation of 
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HeLa cells with FVIIai-F, no internalization could be detected. We therefore 
used in further experiments HeLa cells that were transfected with human TF. 
Transfected HeLa cells showed a 25-fold higher TF activity than non-
transfected cells. Exposure of PS in the outer leaflet of the plasma membrane 
was not affected by the transfection procedure. The FXa-forming activity could 
be completely neutralized by annexin A5 and an anti-TF antibody, indicating the 
critical dependence of both TF and PS. 
We found that the average fluorescent intensity of TF:FVIIai-F on the plasma 
membrane at sites of cell-cell contacts was significantly higher when compared 
with plasma membrane that was not in contact with other cells. Localization of 
TF at cell-cell contacts has been earlier observed by Luther et al. in intercalated 
discs between cardiomyocytes 21. These authors suggested that TF interacts 
via its cytoplasmic domain with the adaptor protein filamin A, which in turn binds 
to actin. However, we found that the mutant TF lacking the intracellular domain 
(TF-∆CT), like wild type TF, was predominantly localized at sites of cell-cell 
contact, suggesting that interaction with filamin A is not involved in the cellular 
distribution of TF. Taken together, these findings suggest that clustering of TF 
at sites of cell-cell contact probably arises from the interaction of the 
extracellular domains of TF. 
Using FVIIai-F indicated that TF-expressing HeLa cells internalize TF:FVIIai-F 
complex into the cytosol. We did not observe internalization of FVIIai-F in wild 
type HeLa cells indicating that TF-FVIIai-F complex formation is essential for 
FVIIai-F endocytosis. Our findings on the internalization of TF are in agreement 
with those reported by Hanssen et al. 22: endocytosis of TF:FVIIai-F complex is 
not dependent on the cytoplasmic domain of TF. This conclusion is based on 
the observation that HeLa cells that express the TF deletion mutant TF-∆CT on 
the cell surface enclose endocytic vesicles containing FVIIai-F. This observation 
indicates that the complex of TF-∆CT and FVIIai-F is internalized by HeLa cells.  
In an earlier study we established that internalization of annexin A5 by HeLa 
cells is dependent on the capacity of annexin A5 to bind PS and to form a 
membrane bound two-dimensional crystal lattice 4.  This proposition is 
supported by the following observations: 1) annexin A5 mutant M1234, which is 
unable to bind to PS, is not internalized by HeLa cells, demonstrating that PS 
binding of annexin A5 is necessary for the endocytosis process, 2) annexin A1, 
which binds PS but does not form a two-dimensional crystal lattice, is not 
internalized by HeLa cells, demonstrating that two-dimensional crystallization is 
essential for the internalization process, and 3) HeLa cells co-incubated with 
annexin A1 and annexin A5 enclosed endocytic vesicles containing both 
annexin A1 and annexin A5, suggesting that annexin A1, bound to the PS-
expressing membrane close to annexin A5 is internalized by HeLa cells. We 
further demonstrated that internalization of annexin A5 by HeLa cells did not 
occur via macropinocytosis, caveolar or clathrin mediated endocytic pathways.  
In the present study we investigated the possibility that internalization of 
annexin A5 by HeLa cells is accompanied by the concomitant internalization of 
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membrane receptors by examining the internalization process of TF in the 
presence of annexin A5. We found that annexin A5, exogenously added to TF-
expressing HeLa cells, internalizes together with TF:FVIIai-F inside the same 
endocytic vesicles indicating that both annexin A5 and TF:FVIIai-F are 
internalized via the same endocytic pathway. To determine whether HeLa cells 
internalize TF:FVIIai-F after annexin A5 induction as previously described for 
apoptotic THP-1 cells 10, we investigated whether PS binding and two-
dimensional crystallization of annexin A5 were necessary for the internalization 
process of TF. The experiments with M1234 and annexin A1 showed that both 
proteins were not internalized together with TF:FVIIai-F by HeLa cells, 
indicating that indeed annexin A5-induced internalization of TF:FVIIai-F might 
be responsible for the internalization process. As earlier shown in the study by 
Kenis et al. 4 for the simultaneous internalization of annexin A5 and annexin A1 
these results suggest that the close presence of TF:FVIIai-F to membrane 
bound annexin A5 results in the concomitant internalization of both annexin A5 
and TF:FVIIai-F. We further observed that TF-expressing HeLa cells enclosed 
two populations of endocytic vesicles: vesicles containing only FVIIai-F and 
vesicles containing both FVIIai-F and annexin A5. This finding suggests that two 
pathways are present for the internalization of TF: 1) a FVIIai-F-induced 
pathway and 2) an annexin A5-induced pathway. This conclusion is based on 
the observation that FVIIai-F is internalized independently of annexin A5. In 
addition annexin A5 is not present in all vesicles that contain FVIIai-F indicating 
that annexin A5 is not internalized in these vesicles and thus not via this 
pathway. Ravassa et al. 10 observed that annexin A5-induced internalization of 
TF:FVIIai-F in apoptotic THP-1 cell results in a significant decrease in FVIIa-
dependent TF activity. We found however that in HeLa cells both FVIIa-induced 
and annexin A5-induced internalization of TF does not result in a decrease of 
FVIIa-dependent TF activity. A possible explanation for this result is that after 
internalization TF is rapidly recycled from the cytosol back to the cell surface. 
Indeed, Iakhiaev et al. showed for fibroblast cells that FVIIa-induced 
internalization of TF is followed by recycling of TF back to the cell surface 23.  
In conclusion our findings indicate that annexin A5 induces internalization of 
TF:FVIIai-F in viable HeLa cells. However, internalization of TF:FVIIai-F by 
viable HeLa cells does not result in a decrease in TF activity, suggesting that 
annexin A5 does not play a significant role in down regulation of the coagulation 
processes initiated by TF-bearing cells.  
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Summary 
Background: Apoptosis induces cellular membrane changes that are thought to 
be linked to thrombotic processes, e.g. surface exposure of procoagulant 
phosphatidylserine (PS), up regulation of tissue factor (TF) and microvesicle 
formation. The latter, though, could down-regulate this cellular response by 
shedding prothrombotic membrane elements, e.g. integrins and TF. To test this 
hypothesis, etoposide treated, apoptotic, monocytic cells (THP-1) were 
examined for rolling and adhesion on adherent platelets and for TF expression. 
Methods and results: Etoposide treatment did not result in a significant change 
in TF antigen expression. However, TF activity, measured in a continuous factor 
Xa generation assay, was increased 5-fold concomitantly with increased 
exposure of PS. Laminar flow adhesion assays specific for interaction between 
P-selectin and P-selectin glycoprotein ligand 1 (PSGL-1) revealed that in 
contrast to non-treated cells, apoptotic cells did not roll or firmly attach on 
adherent platelets. Lack of apoptotic THP-1 platelet interaction could be 
attributed to both a loss of cell surface expressed PSGL-1 and loss of functional 
PSGL-1 as a result of disruption of the binding of PSGL-1 with the cytoskeleton. 
Conclusion: Etoposide-induced apoptosis in THP-1 cells evokes a procoagulant 
response by increasing TF activity associated with an increased PS exposure. 
However, in contrast to TF, PSGL-1 shedding and loss of function, makes that 
apoptotic monocytes are unlikely involved in a thrombotic action because of 
their inability to adhere to an injured vessel wall or developing thrombus. 
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Introduction 
Apoptosis is a genetically conserved process intended to remove unwanted, 
damaged or senescent cells. Proteolytic enzymes known as caspases are 
activated after ligation of death receptors or after the activation of the intrinsic 
pathway with for example etoposide 1. Caspase activation leads to the initial 
stages of leukocyte apoptosis such as changes on the plasma membrane. 
These changes include plasma membrane exposition of phosphatidylserine 
(PS), membrane bleb formation, and generation of microparticles with 
concomitant loss of membrane receptors 2-4. Recently it was hypothesized that 
apoptosis of monocytes contributes to the thrombogenicity of atherosclerotic 
plaques by upregulation of tissue factor (TF) antigen expression 5. In addition, 
cell surface expression of PS catalyzes procoagulant reactions culminating in 
the formation of thrombin 6. An important prerequisite for its thrombogenic 
nature is that the monocyte adheres to a lesion of the vessel wall. Monocytes 
interact via the constitutively expressed membrane protein P-selectin 
glycoprotein ligand-1 (PSGL-1) with perturbed endothelial cells and platelets 
that expose P-selectin 7. P-selectin, stored in Weibel-Palade bodies of 
endothelial cells or alpha-granula of platelets, is expressed on the cell surface 
during vascular injury or inflammatory conditions 8. The interaction of monocyte 
PSGL-1 and P-selectin results in rolling and eventually in stable adhesion of 
these cells 9. A recent study showed that the attachment of PSGL-1 to the actin 
cytoskeleton is essential for the rolling capacity of the cell 10.  Rolling of cells 
expressing PSGL-1 was diminished by disruption of the actin - PSGL-1 
interaction via the ezrin-radixin-moesin complex. Apoptosis of mouse L929 cells 
causes the translocation of moesin from the plasma membrane to the cytosol 11. 
Thus, apoptosis may cause impaired tethering and rolling of monocytes through 
inducing the translocation of moesin with a concomitant loss of PSGL-1 
function. 
To gain more insight into the effects of apoptosis on the prothrombotic role of 
monocytes we investigated the change in procoagulant and adhesive properties 
of the monocytic THP-1 cell line upon treatment with etoposide. Changes in the 
procoagulant response were evaluated with a continuous factor Xa generation 
assay that is dependent both on TF and PS exposure. Expression of TF antigen 
and PS were measured by flow cytometry. A laminar flow adhesion assay was 
used to evaluate the PSGL-1 dependent interaction of apoptotic THP-1 cells 
with a monolayer of surface-adherent platelets. Apoptotic THP-1 cells were 
distinguished from non-apoptotic cells by the use of fluorescently labeled 
annexin A5. Annexin A5 is a protein that binds calcium-dependently with high 
affinity to plasma membranes that expose PS, and is therefore extensively used 
as a tool to detect apoptosis 12, 13. We investigated the effect of apoptosis on the 
interaction of PSGL-1 with the cytoskeleton by flow cytometry and confocal 
scanning laser microscopy (CSLM) using Moesin-EGFP. The results obtained 
show that etoposide-induced apoptosis increases monocytic TF activity as a 
result of increased PS expression. However, the interaction of apoptotic 
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monocytes with P-selectin-expressing cell surfaces was greatly impaired 
because of loss of functional PSGL-1. 
 
Materials and methods 
Reagents 
Etoposide and bovine serum albumin (BSA) were purchased from Sigma. FITC-
labeled anti-TF antibody was obtained from Diagnostica Stago. TF neutralizing 
antibody (TF-5) was purchased from Sanquin. Apoptame-Q was a product from 
MP Biomedicals and Phyco Erythrin (PE)-annexin A5 and propidium iodide 
were purchased from Invitrogen. Annexin A5, alexa 568-annexin A5, Oregon 
Green-annexin A5 and FITC-annexin A5 were from Nexins. Hepes buffer (pH 
7.45) contains 10 mmol L-1 Hepes, 136 mmol L-1 NaCl, 2.7 mmol L-1 KCl, 2 
mmol L-1 MgCl2, 5 mmol L
-1 glucose and 0.1 % BSA. 
 
Cell culture conditions 
The human monocytic THP-1 cell line was obtained from the American Type 
Culture Collection (ATCC) and cultured in RPMI 1640 with glutamax-I and 
Phenol Red (Gibco), supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum (FBS; PAA Laboratories), 25 mmol L-1 Hepes, 100 U mL-1 penicillin and 
100 µg/mL streptomycin. Mouse fibroblast 3T3 cells, obtained from ATCC were 
maintained in DMEM with glutamax-I supplemented with 10% heat-inactivated 
FBS (v/v), 100 U mL-1 penicillin and 100 µg mL-1 streptomycin. Cells were 
maintained at 37ºC in a humidified atmosphere with 5% CO2 and resuspended 
in Hepes buffer containing 3 mmol L-1 CaCl2 immediately before use. 
 
Blood cell preparation 
Washed platelets were prepared as described previously 14. Briefly, blood was 
drawn from healthy volunteers by puncture of antecubital vein and freely 
drained on 0.17 vol. ACD (80 mmol L-1 trisodium citrate, 52 mmol L-1 citric acid 
and 180 mmol L-1 glucose). Platelet rich plasma was obtained by centrifugation 
at 190g for 15 min and diluted with 0.1 vol. of ACD and centrifuged at 650g for 
15 min. The resulting pellet was resuspended in Hepes buffer (pH 6.6) and 0.1 
vol. ACD and centrifuged at 650g for 15 min. The resulting pellet was 
resuspended in Hepes buffer (pH 7.4) at 2x108 platelets mL-1, stored at room 
temperature and used within 3 hours. 
Monocytes were isolated from blood donated from healthy volunteers as 
described earlier (15). Briefly, Human monocytes were isolated from leukocyte-
rich plasma by hyperosmotic NycoPrep 1.068 density gradient centrifugation 
(Nycomed, Norway) and platelets were removed by 300g washes. Monocytes 
were suspended in RPMI containing 10% FBS and used within 4 hours. 
 
Etoposide-induced apoptosis 
THP-1 cells (2x106/mL) in RPMI 1640 supplemented with 10% FBS were 
incubated with etoposide (100 µmol L-1) during 4h at 37°C. Apoptosis was 
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established by binding of FITC-labeled annexin A5 and propidium iodide. 
Analyses were performed with an EPICS XL flow cytometer (Coulter) and data 
were analyzed with WinMDI 2.8. (http://facs.scripps.edu/software.html). 
 
Laminar flow adhesion assay 
Washed platelets (2x108/mL) were allowed to adhere and spread for up to 30 
min at room temperature in rectangular glass micro-capillaries (0.2x2.0 mm and 
length 50 mm; Composite Metal Services). Non-adherent platelets were 
removed by perfusion (wall shear rate 100 s-1) with Hepes buffer (pH 7.4). The 
glass capillaries were mounted on an inverted microscope and a suspension of 
THP-1 cells (2x106/mL) in Hepes buffer containing 2 mmol L-1 Ca2+ was 
perfused into the capillary with a shear rate of 100 s-1. Flow was then stopped to 
allow the cells to settle onto the substrate for 45 s at stasis. Flow was initiated 
(shear rate of 100 s-1) and continued for an additional 4 min. All flow 
experiments were conducted at ambient temperature (21±1oC). Images (225 
µm2) were visualized with a Diaphot 200 inverted microscope (Nikon) by using 
40x oil immersion objective lens. Oregon Green (OG) fluorescence imaging was 
performed with a 485 nm excitation filter, a 505 nm dichroic long-pass filter, and 
a 530 nm emission filter. Data were captured at 25 frames per second with high 
resolution charge-coupled device cameras and recorded on a SVHS recorder 
16. Cells were considered as stationary when they moved less than 1 cell radius 
within 10 s. Rolling cells were defined as cells moving more than their own 
diameter during 10 s before arresting or leaving the platelet monolayer. Rolling 
velocities were determined using Image J software (National Institutes of 
Health).  
 
Flow cytometry 
Non-treated THP-1 cells and etoposide-treated THP-1 cells were incubated for 
30 min on ice in Hepes buffer containing 2 mmol L-1 Ca2+ with FITC-labeled 
anti-TF (Diagnostica Stago) and annexin A5-PE. The same procedure was used 
with FITC-labeled anti-PSGL-1 antibody PL2 (Santa Cruz) and annexin A5-PE. 
The cells were washed ones in Hepes buffer containing 2 mmol L-1 Ca2+ before 
flow cytometry analysis. 
 
Tissue factor activity assay 
TF activity expressed by THP-1 cells was determined as previously described17. 
Briefly, a cell suspension was incubated with a reaction mixture containing: 100 
nmol L-1 factor X, 0.1 nmol L-1 factor VIIa, 3 mmol L-1 CaCl2, and 200 µmol L
-1 
Pentafluor FXa substrate (Pentapharm). Fluorescence tracings were recorded 
in a 48-well plate spectrofluorometer (Spectramax Gemini XS, Molecular 
Devices) at 37°C with an excitation and emission wavelength of 350 and 450 
nm, respectively. Rate of factor Xa generation is expressed as percentage of 
control (non-treated) cells. 
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Plasmid transfection  
The plasmid pMoesin-Enhanced Green Fluorescent Protein (EGFP) containing 
the fusion gene of cDNA of murine moesin and EGFP attached to the carboxy 
amino terminus of moesin was a kind gift of Dr. D. Crouch (University of 
Dundee, Biomedical Research Centre, Dundee UK) 18. 3T3 cells were seeded 
in wells containing a poly-l-lysine coated glass bottom (MatTek Corporation). 
Plasmid pMoesin-EGFP was transfected in 3T3 cells at 60% confluency with 
the transfection agent Fugene 6 (Roche Applied Science). THP-1 cells were 
electroporated with 10 µg mL-1 plasmid pMoesin-EGFP. THP-1 cells were 
suspended in Optimem (Gibco, Life Sciences) at a density of 4x107/mL and 
electroporation was carried out at 250 V and 900 µF with Bio-Rad Gene Pulser-
II.  
 
Confocal Scanning Laser Microscopy (CSLM) 
THP-1 cells were incubated with 100 µmol L-1 etoposide at 37°C and 5% CO2 
for 4h. The THP-1 cells were washed with phosphate buffered saline (PBS). 
The cells were then incubated on ice with alexa 568-annexin A5 and anti-PSGL-
1 antibody KPL1 for 30 min in Hepes buffer containing 2 mmol L-1 Ca2+. In the 
latter case a PE-labeled goat-anti-mouse secondary antibody was used to 
detect bound KPL1. 
The cells were washed once in Hepes buffer containing 2 mmol L-1 Ca2+. The 
cells were then fixed for 15 min in Hepes buffer containing 2 mmol L-1 Ca2+ and 
4% paraformaldehyde (pH 8.0) and washed once in Hepes buffer containing 2 
mmol L-1 Ca2+. The fixed THP-1 cells were mounted in 90% glycerol in 2 mmol 
L-1 Tris-HCl pH = 8.0 with addition of 2% 1,4-diazobicyclo-[2,2,2]-octane 
(Merck). Slides were examined with a confocal scanning laser microscope (Bio-
Rad) equipped with a Crypton/Argon mixed gas laser (Ion Laser Technology). 
Images were recorded and analyzed with NIH Image (National Institutes of 
Health). 
 
Time-lapse fluorescence microscopy 
Imaging was started 24h after transfection of 3T3 cells with pMoesin-EGFP 
using an inverted fluorescence microscope (Zeiss) with appropriate excitation 
and emission filters (Leica Microsystems). Image acquisition was carried out in 
intervals of 15 min using Openlab (Improvision) software. Deconvolution 
software was applied to remove out-of-focus information from selected images 
using the Openlab package.  
 
Statistical analysis 
To determine the statistical significance of means, P values were obtained with 
a Student T-test. Error bars indicate standard deviation.  
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Results 
Apoptotic THP-1 monocytes have an increased tissue factor activity 
In order to asses the effect of apoptosis on the procoagulant activity of THP-1 
cells, we analyzed the plasma membrane expression of TF and PS on non-
treated and etoposide-treated (100 µmol L-1) THP-1 cells. Flow cytometry of 
THP-1 cells using a FITC-labeled anti-TF antibody showed that virtually all 
THP-1 cells expressed TF and only a small subpopulation (5%) of THP-1 cells 
bound annexin A5 (Fig. 1A). Following treatment with etoposide a marked 
increase in annexin A5 binding cells (44% of the total population) was observed 
(Fig. 1B). However, TF expression of apoptotic, annexin A5 binding, cells was 
not diminished when compared with non-treated cells. 
We next determined the effect of etoposide treatment on TF activity, measured 
as the rate of factor VIIa-dependent factor X activation. Fig. 1C shows that 
etoposide-treated cells have a 5-fold higher TF activity than non-treated cells. In 
both cases, factor Xa generation could be fully blocked by a TF neutralizing 
antibody (TF-5) and by annexin A5. No factor Xa generation was detected in the 
absence of THP-1 cells. These findings indicate that THP-1 associated factor 
Xa generation depends on the presence of both TF and PS expressed at the 
THP-1 surface.  
 
 
 
Figure 1,  
TF antigen expression and TF 
activity of etoposide-treated 
THP-1 cells.  
THP-1 cells were incubated  
(4 hours) in the absence (A) and 
presence (B) of 100 µmol L-1 
etoposide at 37oC, labeled with 
FITC-anti-TF and PE-annexin A5 
and analyzed by flow cytometry. 
C, factor VIIa-dependent factor Xa 
generation in the absence and 
presence of 10 µg mL-1 annexin 
A5 and 10 µg mL-1 anti-TF 
antibody (TF-5). 
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Apoptotic THP-1 cells have a diminished interaction with adherent 
platelets 
The results so far established that etoposide treatment of monocytic THP-1 
cells causes an increase in TF-mediated procoagulant activity. We next wished 
to establish whether or not these apoptotic cells can adhere to a surface of 
adherent platelets. Therefore, non-treated and etoposide-treated THP-1 cells 
were perfused into a capillary with a monolayer of adherent platelets, the flow 
was stopped for 45 s and then continued for 4 min. In case of non-treated cells 
a large fraction (90%) of the settled cells rolled over the surface while a few 
remained firmly attached (Fig 2A). Typical tracings of translocating THP-1 cells 
are shown in Fig. 2C. The variance in flow velocities is apparent: cells that role 
continuously, cells that role for a short time and become firmly bound and cells 
that become firmly attached during the stasis phase.  
Flow cytometry analysis of THP-1 suspensions treated with etoposide revealed 
that 33±4% (mean ± SD, n=5) of the total cell population bound annexin A5. 
These cells were considered to be apoptotic. To distinguish apoptotic cells from 
living cells in the flow adhesion assay, cells were incubated for 1 min with OG-
annexin A5 and visualized by fluorescence microscopy. Fig. 2B demonstrates 
that apoptotic THP-1 cells do not role, nor stably adhere when flow is initiated 
after a 45 s period of stasis. Simultaneous real-time phase contrast and 
fluorescence microscopy revealed that OG-annexin A5 negative cells (living 
cells) present in the cell suspension that was treated with etoposide rolled and 
firmly adhered as observed in cell suspensions not treated with etoposide 
shown in Fig. 2A (data not shown).  
To assess more precisely the ability of non-treated cells and apoptotic cells to 
interact with platelets, the number of stationary and rolling cells was determined 
4 min after the restart of the perfusion from 10-15 randomly chosen microscopic 
fields. Fig. 2D shows that for non-treated cells the number of firmly attached 
cells was 8.1±1.1 (mean ± SD) per microscopic field. Occasionally a rolling cell 
was observed (0.2±0.2 cells per microscopic field). The number of stationary 
cells drastically decreased when monocytic cells were treated with etoposide 
(attached THP-1 cells versus attached etoposide treated THP-1 cells, P value < 
0.025). The number of adherent apoptotic cells was 1.3±0.9 (mean ± SD) per 
microscopic field. Interestingly, treatment of THP-1 cells with the PSGL-1 
antibody KPL1 (10 µg mL-1) 19 resulted in the same drastic reduction in the 
number of adherent cells (Fig. 2D). To confirm that monocytes isolated from 
human blood are equally affected by etoposide as demonstrated for THP-1 
cells, flow adhesion assays were performed with non-treated and etoposide-
treated monocytes. After 4 min perfusion of non-treated cells (1.5x106 cells/mL) 
through capillaries with adherent platelets, the number of rolling cells was 
13.4±3.2 (mean ± SD) per microscopic field. Only a few stationary cells were 
observed. Etoposide treatment greatly reduced the number of rolling cells 
(1.4±1.4 per microscopic field). No stationary cells were observed.  
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Figure 2, Interaction of THP-1 cells with a monolayer of adherent platelets. 
A: a suspension of THP-1 cells (2x106/mL) was infused in a glass capillary coated with a 
monolayer of platelets. After 45 s of stasis the flow was started (t=0 s) and phase 
contrast images were grabbed at the times indicated. B: a similar experiment as 
described in panel A but with etoposide-treated THP-1 cells (2x106/mL) incubated with 
OG-annexin A5 and visualized by fluorescence microscopy. C: representative 
translocations of THP-1 cells in the direction of the flow. D: the number of firmly adherent 
(black bar) and rolling cells (gray bar) as determined 4 min after the restart of perfusion 
with non-treated cells, apoptotic cells and cells that were treated with 10 µg mL-1 of the 
anti-PSGL-1 antibody KPL-1 from 10-15 different microscopic fields in 3 independent 
perfusion experiments.  
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Figure 3, Effect of etoposide on PSGL-1 exposure. THP-1 cells were incubated for 4 
hours in the absence (A) and presence (B) of 100 µmol L-1 etoposide at 37°C, labeled 
with FITC-anti-PSGL-1 and PE-annexin A5 and then analyzed by flow cytometry. Non-
treated cells (C) and etoposide-treated cells (D) were stained with anti-PSGL-1 antibody 
(KPL1) followed by a secondary PE-goat-anti-mouse antibody (red) and FITC-annexin 
A5 (green) and analyzed by CSLM.  
 
Apoptosis induces loss of functional PSGL-1 
We examined two possibilities which could be responsible for the altered rolling 
and adherence behavior of apoptotic THP-1 cells. Firstly, apoptosis could 
induce the shedding of PSGL-1 from the THP-1 cell surface and secondly, 
apoptosis could cause an impaired attachment of PSGL-1 to the actin 
cytoskeleton resulting in loss of function. We first compared the surface density 
of PSGL-1 before and after treatment with etoposide. THP-1 cells expressed 
PSGL-1 on the cells surface as shown with flow cytometry using a FITC-labeled 
anti-PSGL-1 antibody (Fig. 3A). Flow cytometry demonstrated that apoptotic, 
annexin A5 binding, THP-1 cells have a reduced surface density of PSGL-1 
(Fig. 3B). The mean fluorescence intensity (MFI) for FITC-labeled anti-PSGL-1 
antibody on annexin A5 binding cells was 28% compared to non annexin A5 
binding cells. CSLM of non-treated THP-1 cells that were stained with the 
primary antibody KPL1 and a secondary PE labeled goat-anti-mouse antibody 
showed the presence of PSGL-1 in high density at discrete sites on the plasma 
membrane (Fig. 3C). However, PSGL-1 could not be detected on the plasma 
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membrane of etoposide treated THP-1 cells that bind FITC-annexin A5 (Fig. 
3D). Pre-incubation of THP-1 cells with 10 µmol L-1 pan caspase inhibitor 
apoptame-Q prevents etoposide-induced loss of PSGL-1 (data not shown), 
confirming that the apoptotic process reduces the amount of surface-expressed 
PSGL-1. 
An alternative or additional explanation for the aforementioned impaired 
adhesion properties of apoptotic THP-1 cells is loss of the moesin-controlled 
association of PSGL-1 to actin in microvilli.  It has been demonstrated that the 
association of PSGL-1 with the actin cytoskeleton is essential for the rolling 
ability of leukocytes over P-selectin exposing cells 10. This notion prompted us 
to examine the cellular location of moesin during etoposide treatment. Moesin 
location was examined with a plasmid containing a cDNA for green fluorescent 
protein tagged to murine moesin. We first examined the location of moesin-
EGFP during etoposide treatment in murine 3T3 cells to study the behavior of 
moesin in a homologous cellular system. The location of moesin-EGFP in 
transfected 3T3 cells was followed during apoptosis by time lapse fluorescence 
microscopy taking images with intervals of 15 min. Transfected 3T3 cell showed 
a patchy-like localization of moesin-EGFP at the plasma membrane. Etoposide 
treatment induced a dissociation of moesin-EGFP from the plasma membrane 
into the cytosol concomitant with alexa 568-labeled annexin A5 binding to the 
plasma membrane. Apoptosis-induced translocation of moesin-EGFP could be 
inhibited by incubation with apoptame-Q (data not shown). We next turned to 
THP-1 cells to examine moesin-EGFP location after etoposide treatment. The 
location of moesin in THP-1 cells was visualized by CSLM after electroporation 
of THP-1 cells with plasmid containing the moesin-EGFP gene. CSLM 
demonstrated that moesin-EGFP is located at the plasma membrane and in the 
cytosol of THP-1 cells (Fig. 4A). In etoposide treated THP-1 cells moesin-EGFP 
was only seen in the cytosol and not at the plasma membrane of annexin A5 
binding THP-1 cells (Fig. 4D, 4E). These findings indicate translocation of 
moesin-EGFP from the plasma membrane to the cytosol before or during the 
exposition of PS on the plasma membrane both in murine 3T3 cells and human 
THP-1 cells.  
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Figure 4, Etoposide-induced translocation of moesin-EGFP in THP-1 cells.  
THP-1 cells transiently expressing moesin-EGFP were incubated for 4 hours in the 
absence (A, B, C) and presence (D, E, F) of 100 µmol L-1 etoposide at 37°C. Alexa 568-
annexin A5 is absent on THP-1 cells (B), Moesin-EGFP is present in both the membrane 
bound and in the free cytosolic form in THP-1 cells (C). Moesin-EGFP is present in 
cytosolic but not in membrane bound form in etoposide treated THP-1 cells (D), THP-1 
cell with plasma membrane bound Alexa 568-annexin A5 (E). F depicts the merged 
images of D and E.  
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Discussion  
The processes involved in the interaction between leukocyte PSGL-1 and cells 
exposing P-selectin are currently under intense investigation. PSGL-1 is a 
leukocyte membrane protein involved in the initial rolling and attachment events 
of leukocytes on platelets and endothelial cells exposing P-selectin and/or L-
selectin. Recent studies demonstrate that the interaction of leukocyte expressed 
PSGL-1 with membrane exposed P-selectin not only plays a role in 
inflammatory processes but also in haemostasis 20, 21. 
In this study we examined apoptosis-induced changes in PS exposure, TF and 
PSGL-1 expression on the plasma membrane of monocytic THP-1 cells. We 
established with flow cytometry and a factor X activation assay that TF is 
present on THP-1 monocytes. During etoposide-induced apoptosis TF 
expression was not changed. However the activity of TF was increased. The 
apoptosis-induced increase in TF activity is associated with the externalization 
of PS. We conclude that apoptosis-induced membrane exposure of PS 
transforms cryptic TF into active TF by supplying anionic phospholipids that 
support the assembly of the extrinsic tenase complex. Etoposide-induced up-
regulation of TF activity by circulating monocytes poses a risk of thrombosis on 
patients treated with this cytostatic agent, provided that the etoposide-treated 
monocytes retain the ability to adhere to vascular sites with activated platelets 
and endothelial cells. In this paper we demonstrate for THP-1 cells that 
etoposide induces apoptosis and reduces concomittantly the adhesive 
properties of THP-1 cells by downregulation of surface expression of functional 
PSGL-1. Since differences between THP-1 cells and human blood monocytes 
have been reported we compared both cell types on their adhesive and rolling 
properties 22. Similar to THP-1 cells, the human monocytes lose their ability to 
adhere and roll on a layer of activated platelets if treated with etoposide, 
indicating that THP-1 cells are a representative model for monocyte interaction 
with platelets. 
Flow cytometry and CSLM indicate that annexin A5 binding cells have a 
reduced surface density of PSGL-1. We hypothesize that apoptosis-induced 
shedding of PSGL-1 bearing microparticles or protease-catalyzed cleavage of 
the extracellular domain of PSGL-1 causes loss of cell surface-located PSGL-1 
during externalization of PS. Alternatively or additionally, the inability of 
apoptotic THP-1 cells to form firm interactions with adherent platelets could also 
be caused by an impaired moesin-mediated interaction between PSGL-1 and 
the actin cytoskeleton 10. Similar to observations made by Kondo et al 11 in 
mouse L929 cells, we have shown that moesin is not present in the membrane 
bound form during apoptosis of mouse 3T3 cells and human THP-1 cells. 
Snapp et al have shown that the association of PSGL-1 with the actin 
cytoskeleton is essential for the rolling ability of leukocytes over P-selectin 
exposing cells 10. We propose that translocation of moesin during apoptosis and 
the concomitant dissociation of PSGL-1 from the actin cytoskeleton decreases 
the interaction of PSGL-1 with P-selectin. Collectively, our data suggest that 
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apoptosis induces two processes that impair the interaction of THP-1 cells with 
P-selectin-bearing cells: a) loss of membrane associated PSGL-1 and b) loss of 
functionality of membrane-associated PSGL-1.  
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Introduction  
Annexin A5 is a protein of 36 kDalton that binds in a calcium-dependent manner 
to phosphatidylserine (PS)-containing membrane surfaces. Membrane binding 
is followed by the formation of annexin A5 trimers which subsequently 
associate, via protein-protein interactions, to form larger structures such as 
dimers of trimers and trimers of trimers 1, 2. The association of trimers leads to 
the formation of a two-dimensional crystal lattice which is characterized by P3 
or P6 symmetry. In this thesis we have investigated whether the PS binding 
property of annexin A5 and the subsequent trimer formation can influence the 
membrane dynamics of the PS-expressing plasma membrane. In the studies 
presented here we have chosen to examine PS binding of annexin A5 with the 
PS-containing outer membrane surface of cells because: (i) The calcium 
concentration present in the circulation is 1000 µmol L-1 and in the cytosol, at 
resting level, is approximately 0.1 µmol L-1  3-5. (ii) The half maximal adsorption 
of annexin A5 to a phospholipid layer consisting of a ratio of 20/80 mol% and 
5/95 mol% of phosphatidylserine to phosphatidylcholine occurs at a calcium 
concentration of 220 and 1500 µmol L-1 respectively 6. From both conditions we 
can conclude that annexin A5 binding to a PS-containing membrane surface 
does much more readily occur when annexin A5 is present in the circulation 
than in the cytosol. 
Annexin A5 has been suggested to function as an anti-coagulant protein by 
competing for PS binding sites in a calcium-dependent manner with 
prothrombin on a PS-expressing membrane surface 7. Apart from playing a role 
in the anticoagulant arm of the thrombotic system annexin A5 has also been 
suggested to play a role in other processes occurring on a PS-expressing cell 
surface. For instance, binding of annexin A5 to the plasma membrane of 
apoptotic cells has been reported to influence the progress of the apoptotic 
program 8. Both examples give reason to expect that annexin A5 might play a 
role on other cell types during various circumstances. In the studies presented 
in this thesis we have investigated the effect of annexin A5 binding to PS on 
various cell types. In chapter 3 we examined PS binding of annexin A5 on 
apoptotic Jurkat cells and viable HeLa tumor cells. It was shown that PS binding 
of annexin A5 influences membrane dynamics of the PS-expressing cell surface 
by inhibiting apoptotic body formation and by inducing a novel endocytic 
pathway that depends on PS-expression. Here we discuss the implication of the 
annexin A5-mediated inhibition of apoptotic body formation in relation to 
physiological processes in which apoptotic bodies play a role. In chapter 3 and 
4 we examined endocytosis of annexin A5 and the annexin A5-induced 
endocytosis of the membrane protein tissue factor in viable HeLa cells. We 
discuss the physiological relevance of this endocytic pathway. And finally in 
chapter 5 we examined plasma membrane changes occurring during apoptotic 
cell death of monocytes.  
 
 107 
Function of the annexin A5 two-dimensional crystal lattice 
In chapter 3 is investigated whether plasma membrane dynamics of PS-
expressing cells is influenced by the trimer based two-dimensional crystal lattice 
formed by annexin A5. The two-dimensional crystal lattice has been suggested 
to function in several membrane-related processes. The coagulation proteins 
factor Xa, factor Va and prothrombin associate on a PS-expressing membrane 
to form the prothrombinase complex. Andree et al. proposed that annexin A5 
not only inhibits the formation of the prothrombinase complex by competing for 
PS binding sites but also by the formation of the two-dimensional crystal lattice9. 
They suggested that the membrane bound crystal lattice of annexin A5 inhibits 
the formation of the prothrombinase complex by preventing the lateral 
movement of the coagulation factors on the PS-expressing membrane surface. 
Another function of the two-dimensional crystal lattice was suggested by Gidon-
Jeangirard et al. 8. Cells induced to undergo apoptosis are characterized by 
membrane changes such as externalization of PS to the outer membrane leaflet 
and shedding of microparticles. Gidon-Jeangirard et al. observed that cell 
surface binding of annexin A5 resulted in the inhibition of microparticle 
generation by cells which were undergoing apoptotic cell death 8. They 
proposed that inhibition of microparticle generation by annexin A5 was the 
result of a physical constraint on the cell surface carried out by the crystal lattice 
formed by annexin A5 on the membrane.  
 
Inhibition of microparticle generation by annexin A5 
We studied the ability of annexin A5 to inhibit microparticle generation with a 
model system comprised of T-lymphoma Jurkat cells induced to execute 
apoptosis with an anti-body directed against the Fas-receptor. Annexin A5 was 
able to inhibit, dose-dependently, the generation of Jurkat cell derived 
microparticles. In order to determine the role of the two-dimensional crystal 
lattice formed by annexin A5 in inhibiting the generation of microparticles we 
used the annexin A5 mutant 2D1-6 which binds PS but is unable to form a two-
dimensional crystal lattice. We found that 2D1-6 was able to inhibit microparticle 
generation indicating that two-dimensional crystal formation is not involved in 
inhibiting the generation of microparticles. This was further supported by 
experiments with annexin A1 (a member of the annexin family which binds PS 
but is unable to form a two-dimensional crystal lattice) which showed that 
annexin A1 was also able to inhibit microparticle generation. These experiments 
demonstrate that PS binding of annexin A5 and not two-dimensional crystal 
formation causes the inhibition of microparticle generation. How annexin A5 
inhibits microparticle generation is at present unclear.  
In recent years microparticles, containing (intrinsic membrane) proteins, have 
been suggested to function in intercellular communication processes and in the 
transfer of plasma membrane receptors between cells 10-16. Monocytes for 
instance, generate microparticles carrying the membrane proteins tissue factor 
and P-selectin Glycoprotein Ligand-1 (PSGL-1). These microparticles have 
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been reported to accumulate on P-selectin-expressing platelets located at a 
developing thrombus during vascular injury 14, 15. Annexin A5 might regulate 
these microparticle-mediated processes if the following conditions are fulfilled (i) 
the microparticles express PS on the membrane surface and (ii) annexin A5 is 
present in the circulation in a concentration that results in inhibition of 
microparticle generation.  
 
The annexin A5-PS endocytic pathway  
Our investigations into the inhibition of microparticle generation by annexin A5 
revealed that annexin A5 but not annexin A5 mutant M1234 (which is unable to 
bind calcium and consequently does not bind PS) was internalized by apoptotic 
Jurkat cells and HeLa tumor cells. Internalization of annexin A5 was shown to 
be mechanistically distinct from macropinocytosis or from clathrin or caveolar-
mediated endocytosis. These results indicate that annexin A5 is internalized via 
a novel endocytosis pathway that requires the cell surface expression of PS.  
Annexin A5 has been reported to function as a plasma membrane localized 
calcium conducting ion-channel 17, 18. Calcium signaling plays a role in the 
initiation of various biochemical processes. It might be possible that the 
formation of annexin A5 calcium channels is involved in the initiation of annexin 
A5 endocytosis. However, channel formation of annexin A5 through the plasma 
membrane occurs, according to current models, in an environment with a low 
calcium concentration. Internalization of annexin A5 is consequently not initiated 
by channel formation because of the high calcium concentration that was used 
in our experiments.  
Having ruled out the involvement of annexin A5-mediated calcium signaling in 
the endocytosis process we examined the involvement of the two-dimensional 
crystal formed by annexin A5. Apoptotic Jurkat cells and HeLa tumor cells were 
incubated with fluorescently labelled 2D1-6. CSLM analysis did not show the 
presence of endocytic vesicles containing 2D1-6 indicating that two-dimensional 
crystal formation of annexin A5 is involved in the endocytosis process. This 
conclusion was further corroborated by experiments that showed that annexin 
A1 also failed to internalize in apoptotic Jurkat cells and HeLa tumor cells.  
A possible mechanism for the endocytosis of annexin A5 might be the annexin 
A5-induced curvature of the membrane which leads to the formation of an 
endocytic vesicle. The tertiary structure of annexin A5 shows that its 
phospholipid binding side has a convex shape 19. When bound to the 
membrane annexin A5 forms trimers of which each monomer retains the 
convex shape at its phospholipid binding side 20, 21. Domain III is the most 
distant from the membrane surface and domain II the closest 20. All four 
domains contain a calcium-binding motif making it possible that membrane-
bound annexin A5 influences the PS-expressing membrane surface to adopt a 
shape that is complementary to the convex shape of the annexin A5 molecule. 
We propose that the trimers bend the membrane and provide the driving force 
for the internalization of membrane-bound annexin A5. 
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Annexin A5-induced endocytosis of tissue factor 
Annexin A5 has been proposed the play a role in anti-coagulant processes by 
binding to PS and by the formation of a two-dimensional crystal lattice. PS 
binding of annexin A5 prevents binding of factor Va, Xa and prothrombin to the 
PS-expressing cell surface 7. And the two-dimensional crystal lattice of annexin 
A5 molecules prevents the lateral movement of PS bound Va, Xa and 
prothrombin to combine into the pro-thrombinase complex 9. In a recent study 
by Ravassa et al. a third anti-coagulant mechanism in which annexin A5 plays a 
role was proposed 22. Tissue factor (TF) was shown to be internalized 
concomitantly with annexin A5 by apoptotic PS-expressing THP-1 
macrophages. TF is the cell surface receptor of the serine protease factor VIIa 
(FVIIa) 23. The complex of TF with FVIIa converts the inactive factor X (FX) into 
the active factor X (FXa). The formation of the complex of TF, FVIIa and FX and 
the subsequent conversion of FX into FXa requires the presence of PS on the 
cell surface. Ravassa et al. showed that annexin A5-induced internalization of 
TF on apoptotic THP-1 cells resulted in a significant decrease in TF activity 22. 
This result indicates that annexin A5 plays a role in anti-coagulant processes 
initiated by TF-expressing apoptotic cells. In this thesis we have investigated 
whether annexin A5 also plays a role in down regulating TF activity on living 
HeLa cells. The physiological relevance of annexin A5-induced TF 
internalization during apoptosis is not well understood and can be debatable. 
Apoptotic cells that express PS on the plasma membrane are rapidly removed 
from tissue by phagocytes 24. If the annexin A5-PS endocytic pathway plays a 
role of significance it has to be active before the apoptotic cell is cleared by 
phagocytosis. To investigate the possibility that annexin A5-induced 
endocytosis of TF occurs in living cells we studied TF internalization in a model 
system comprised of living HeLa cells expressing TF cDNA. Using this model 
system we demonstrated annexin A5-induced endocytosis of TF by showing 
that fluorescently labeled FVIIa was internalized by annexin A5 in HeLa cells 
transfected with TF cDNA. This indicates that the annexin A5 endocytic 
pathway can internalize TF in living cells. Annexin A5-induced internalization of 
TF did however not cause a significant decrease in TF activity on living HeLa 
cells. These results indicate that annexin A5 plays a role in down regulating TF 
activity on apoptotic cells but not on living cells. A possible explanation for this 
result is that living HeLa cells recycle TF back to the cell surface while recycling 
of TF does not occur in apoptotic THP-1 cells. Apoptotic cells contain active 
proteolytic enzymes known as caspases 25. The intracellular proteins 
responsible for recycling receptors back to the cell surface might be the target 
of proteolytic cleavage by caspases with the result that TF is retained in the 
cytosol of apoptotic THP-1 macrophages.  
In recent years cell surface expression of PS has been found to occur on 
several cell types under specific conditions and independent of cell death. For 
instance, monocytes that differentiate into macrophages or monocytes 
stimulated with the dimeric protein galectin-1 expose PS 26-28. The results 
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presented in chapter 4 raise the possibility that the annexin A5-PS endocytic 
pathway might by involved in the internalization of TF in these cell types. The 
data presented in chapter 4 suggest that the annexin A5-PS endocytic pathway 
might also be involved in the internalization and regulation of plasma 
membrane-localized receptors besides TF. Other potential membrane receptors 
that could be internalized by the annexin A5-PS endocytic pathway might be 
receptors homologous to TF such as the interferon-gamma (IFN-γ) receptor and 
other receptors of the class II cytokine receptor family 29.  
 
Functionality of cell surface expressed PSGL-1 during apoptosis 
In chapter 5 we studied the effect of plasma membrane changes occurring 
during apoptosis on monocyte expressed TF and PSGL-1. Monocytes generate 
microparticles that express the membrane proteins TF and PSGL-1 14, 15 
indicating that TF and PSGL-1 are closely localized to each other on the cell 
surface. Because TF was shown to be internalized by annexin A5 we 
investigated the possibility that the annexin A5-PS endocytic pathway affects 
the functionality of PSGL-1 by internalizing this protein. Our investigations into 
the functionality of PSGL-1 on the apoptotic plasma membrane showed 
however that this protein had lost its functionality independent from the annexin 
A5-PS endocytic pathway. Monocytes are able to roll and adhere to P-selectin 
exposing adhered platelets via cell surface expressed PSGL-1 30. We 
demonstrated that THP-1 monocytes had lost this ability during the apoptotic 
process because of loss of function of cell surface expressed PSGL-1 and 
because of disruption of the binding of PSGL-1 to the cytoskeleton.  
 
Future perspectives of annexin A5 in anti-tumor treatment 
Apoptotic cells are frequently found in pathologically insulted tissues. Solid 
tumors, for example, often contain apoptotic PS-expressing cells because of the 
insufficient supply of oxygen and nutrients into the tumor tissue. In addition, the 
number of apoptotic cells present in the tumor increases when cancer patients 
are treated with cytostatic apoptosis-inducing agents. PS-expressing endothelial 
cells are further found in angiogenic blood vessels present in solid tumors 31. 
The presence of PS-expressing cells in tumors offers an opportunity to devise 
strategies to treat tumors using annexin A5 as a targeting agent. 
An example of such a strategy is described in a study recently published by 
Bondanza and co-workers 32. Dendritic cells (DC) are able to phagocytose 
apoptotic tumor cells and to present apoptotic tumor cell-derived antigens via 
the major histocompatibility complex I (MHC-I) on the cell surface 33. MHC-I 
presented tumor antigens then become available for recognition by cytotoxic T-
lymphocytes. The strategy Bondanza and co-workers used was based on a 
difference in phagocytic abilities displayed by macrophages and DC’s. 
Macrophages recognize and phagocytose PS-expressing apoptotic cells via a 
putative PS-receptor 24. DC’s, however, are less dependent on PS recognition 
during phagocytosis of apoptotic cells because DC’s actively internalize cells 
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and substrates via macropinocytosis in a constitutive manner 32, 34, 35. Bondanza 
and co-workers introduced apoptotic lymphoma cells concomitantly with 
annexin A5 into the circulation of mice. They reasoned that disrupting the PS-
dependent clearance of apoptotic cells by macrophages with annexin A5 would 
result in unscavenged apoptotic tumor cells, available for uptake and 
processing by DC’s. The DC’s would subsequently present tumor derived 
antigens via MHC molecules on the cell surface and activate a cytotoxic T- 
lymphocyte response. Bondanza and co-workers observed a cyotoxic T- 
lymphocyte response against lymphoma tumor cells when the same mice were 
later challenged with viable lymphoma cells. The cytotoxic T- lymphocyte 
response in these mice resulted in a significant decrease in tumor development.  
Two other strategies which are currently under development are possible: (i), 
using the PS binding property of annexin A5 it might be possible to target toxic 
agents to PS-expressing cells present on or inside the tumor. This strategy has 
been used earlier for targeting the bacterial pseudomonas exotoxin to malignant 
glioma tumor cells. Glioma tumor cells are a type of neural tumor cells which 
overexpress the interleukin-4 receptor on the cell surface. Puri and co-workers 
created a chimera protein that consisted of the exotoxin protein tagged to 
interleukin 4 36. The interleukin 4 part of the chimera protein was used in this 
strategy as a tumor-targeting agent. Once introduced close to the glioma tumor 
this chimera protein would accumulate at the tumor by binding to the interleukin 
4 receptor. The accumulated chimera protein would then exert its toxic effect on 
the tumor cells. A similar strategy is now pursued by Reutelingsperger and co-
workers. The PS binding property of annexin A5 is used to target pseudomonas 
exotoxin tagged to annexin A5 to PS-expressing cells in the tumor. This 
strategy aims to accumulate a high concentration of pseudomonas exotoxin 
inside the tumor which would subsequently decrease in size because of the 
toxic effects of the exotoxin.  
 (ii), The PS binding property of annexin A5 could also be used to specifically 
target apoptosis-inducing cytostatic agents to the site in the body where the 
solid tumor is located. It is desirable to administrate cytostatic agents only to the 
site where the solid tumor is located. Cytostatic agents are introduced into the 
circulation which leads to a systemic distribution of the agent. The systemic 
distribution of the cytostatic agent leads to the destruction of the tumor but also 
to damage of organs that do not contain tumor cells. A strategy which aims to 
solve this problem is currently under development by Reutelingsperger and co-
workers. Reutelingsperger and co-workers use annexin A5 to target liposomes 
that contain a cytostatic agent to PS-expressing tumor cells. Annexin A5 tagged 
liposomes containing cytostatic agents are introduced into the circulation. These 
liposomes subsequently accumulate on PS-expressing cells present on the 
solid tumor. Annexin A5 targeting of liposome-containing cytostatic agents leads 
to destruction of the tumor while non-specific distribution to other parts in the 
body is prevented.  
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In this thesis we have described the existence of an endocytic pathway present 
on PS-expressing cells that internalize annexin A5. Other strategies in anti-
tumor treatment can be envisioned that use the capacity of annexin A5 to 
internalize into PS-expressing cells. One such strategy might be the introduction 
of apoptosis-inducing agents in PS-expressing endothelial cells lining the inner 
surface of angiogenic blood vessels present inside solid tumors.  
  
Conclusions 
Previously annexin A5 was known to bind to PS-expressing cell surfaces in a 
calcium-dependent manner. In this thesis it was shown that annexin A5 not only 
binds to the PS-expressing cell surface but that PS binding and the formation of 
a two-dimensional crystal lattice also influences the membrane dynamics of the 
PS-expressing cell surface. It was shown that annexin A5 binding to PS inhibits 
microparticle formation by PS-expressing apoptotic Jurkat lymphoma cells. It 
was further shown that annexin A5 induces internalization of PS microdomains 
by inducing curvature of the cell surface. In addition, annexin A5 induces 
internalization of the intrinsic membrane protein TF present in the PS 
microdomain. The annexin A5-PS endocytic pathway also makes it possible to 
devise novel strategies in anti-tumor treatment.  
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Inleiding 
De annexine familie bestaat uit eiwitten die gemeenschappelijke structurele en 
functionele eigenschappen hebben. Annexine A5, een lid van deze familie, is in 
staat om in de aanwezigheid van calcium ionen aan een membraan te binden 
die negatief geladen fosfatidylserine (PS) bevat. De tertiaire (drie-dimensionale) 
structuur van annexine A5 bestaat uit vier domeinen, met elk 70 aminozuren, 
die cyclisch georganiseerd zijn. Annexine A5 moleculen gaan in een oplossing, 
in afwezigheid van calcium of een PS bevattende membraan, geen interacties 
met elkaar aan. Echter membraan gebonden annexine A5 moleculen 
(monomeren) associëren met elkaar, via eiwit-eiwit interacties, tot structuren 
(trimeren) die elk opgebouwd zijn uit drie annexine A5 moleculen. Trimeren 
kunnen vervolgens een twee-dimensionaal membraan gebonden kristal rooster 
vormen die beschreven kan worden door middel van P3 of P6 rotatie 
symmetrie.  
In dit proefschift hebben we onderzocht of binding van annexine A5 aan PS en 
de daaropvolgende trimer vorming invloed heeft op de dynamica van de PS 
bevattende plasma membraan. We hebben gekozen om de interactie van 
annexin A5 met PS te bestuderen op PS bevattende cel oppervlakken die bloot 
gesteld zijn aan de omgeving buiten de cel om de volgende redenen. (1) 
Annexin A5 moleculen komen voor in het binnenste van een cel en in bloed. (2) 
De calcium concentratie binnen in een cel is ongeveer 0,1 micro-molair en de 
calcium concentratie van bloed is 1000 micro-molair. (3) Annexine A5 kan het 
oppervlak van een PS bevattende membraan die bestaat uit 20 mol% en 5 
mol% PS voor de helft bezetten bij een calcium concentratie die gelijk is aan 
respectievelijk 1500 en 220 micro-molair. Uit het voorgaande kan afgeleid 
worden dat annexine A5 veel makkelijker bindt aan een PS bevattende 
membraan als dit eiwit zich in het bloed bevindt. 
Er zijn verschillende processen waarbij een PS bevattende membraan een rol 
speelt. Bloed plaatjes die aan collageen vast gehecht zitten brengen PS tot 
expressie op het membraan oppervlak. De bloed stollings factoren Va, Xa en 
prothrombine kunnen op dit PS bevattende membraan binden en het 
prothrombinase eiwit complex vormen. Het prothrombinase complex is 
verantwoordelijk voor de omzetting van het inactieve eiwit prothrombine naar 
het actieve thrombine. Thrombine is daaropvolgend betrokken bij het omzetten 
van het inactieve en oplosbare eiwit fibrinogeen naar fibrine. Fibrine moleculen 
kunnen onderling associaties aangaan die leiden tot de formatie van lange 
polymeren (kettingen) die bestaan uit fibrine moleculen. De fibrine polymeren 
worden gevormd op plaatsen waar een beschadiging van het bloedvat heeft 
plaats gevonden. Het netwerk van bloed plaatjes en fibrine polymeren is 
verantwoordelijk voor het voorkomen van het lekken van bloed uit het 
beschadigde bloedvat.  
Er is voorgesteld dat annexine A5 moleculen een rol spelen in het remmen van 
het bloed stollings proces. Annexin A5 moleculen kunnen een competitie 
aangaan met de stollings factoren prothrombine, factor Va en factor Xa door het 
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binden aan een PS bevattende membraan. In dit competitie proces kunnen 
annexine A5 moleculen de vorming van het prothrombinase complex 
voorkomen en de daaropvolgende activering van het eiwit thrombine. Een 
ander proces waarbij een PS bevattende membraan een rol speelt is het cel 
dood proces. De cel inhoud wordt van de omgeving afgeschermd door middel 
van een plasma membraan. De zijde van de plasma membraan die bloot 
gesteld is aan de omgeving bevat normaal geen negatief geladen PS 
moleculen. In geval van een beschadiging van de cel, cellen die een hoge 
ouderdom hebben of cellen die ongewild zijn kan de plasma membraan PS 
bevatten. Het presenteren van PS op de plasma membraan aan de omgeving 
van de cel is één van de vele eigenschappen die karakteristiek zijn voor een cel 
die het cel dood proces ondergaat. Er is voorgesteld dat binding van annexine 
A5 op de PS bevattende plasma membraan het verloop van het cel dood 
proces kan vertragen. De voorgaande voorbeelden geven aanleiding tot de 
gedachte dat annexin A5 invloed heeft op biochemische processen die zich 
afspelen op de PS bevattende plasma membraan van cellen. In dit proefschrift 
hebben we de invloed van annexine A5 op verschillende processen die zich 
afspelen op de PS bevattende plasma membraan onderzocht. Tijdens het cel 
dood proces wordt er niet alleen PS op de plasma membraan gepresenteerd 
maar er worden ook bolvormige membraan omsloten fragmenten (micro-
partikels) afgescheiden. In hoofdstuk 3 staat beschreven dat annexine A5 de 
vorming van micro-partikels kan remmen. Er staat ook beschreven dat annexine 
A5, na binding aan de PS bevattende plasma membraan, opgenomen wordt 
door de cel (endocytose) via een nog niet eerder beschreven endocytose 
proces. In hoofdstuk 4 staat beschreven dat annexine A5 verantwoordelijk is 
voor de endocytose van het membraan eiwit tissue factor. En in het laatste 
hoofdstuk staan de veranderingen beschreven die optreden op de plasma 
membraan van monocyten die het cel dood proces ondergaan.  
  
Welke rol speelt het twee-dimensionale kristal van annexine A5 op de 
plasma membraan? 
In hoofdstuk 3 hebben we onderzocht wat de rol is van het twee-dimensionale 
kristal van annexine A5 op de PS bevattende plasma membraan. Er zijn 
verschillende voorstellen gedaan voor de rol van het twee-dimensionale kristal 
van annexine A5 op de plasma membraan. De bloed stollings factoren Va, Xa 
en prothrombine kunnen het prothrombinase complex vormen op een PS 
bevattende membraan. Harry Andree en collega’s hebben voorgesteld dat 
annexine A5 de vorming van het prothrombinase complex niet alleen kan 
remmen via een competitie proces voor PS binding maar ook via de vorming 
van het twee-dimensionale kristal rooster. De bloed stollings factoren Va, Xa en 
prothrombine binden en bewegen eerst op het oppervlak van de PS bevattende 
membraan alvorens het prothrombinase complex te vormen. Harry Andree en 
collega’s hebben voorgesteld dat het twee-dimensionale kristal rooster van 
annexine A5 de beweging voorkomt van de stollings factoren die al aan PS 
  
120 
gebonden zijn zodat er geen prothrombinase complex gevormd kan worden. 
Een andere rol van het twee-dimensionale kristal rooster is voorgesteld door 
Gidon-Jeangirard en collega’s. Tijdens het cel dood proces worden bolvormige 
en membraan omsloten fragmenten (micro-partikels) van de PS bevattende 
plasma membraan afgescheiden. Gidon-Jeangirard en collega’s namen waar 
dat annexine A5 de vorming van micro-partikels kon remmen. Zij stelden voor 
dat de aanwezigheid van een mechanische beperking op de plasma membraan 
in de vorm van het twee-dimensionale kristal rooster van annexine A5 
verantwoordelijk was voor remming van micro-partikel vorming.  
 
Remming van micro-partikels door annexine A5 
Micro-partikel vorming werd bestudeerd door middel van een model systeem 
bestaande uit Jurkat lymfoma cellen die gestimuleerd werden om het cel dood 
proces te ondergaan met behulp van een anti-lichaam gericht tegen de Fas-
receptor. We namen waar dat annexine A5, dosis afhankelijk, in staat was de 
vorming van micro-partikels te remmen. We gebruikten de annexine A5 mutant 
2D1-6 om te testen of het twee-dimensionale kristal rooster van annexine A5 
verantwoordelijk was voor de remming van micro-partikels. De annexine A5 
mutant 2D1-6 kan aan PS binden maar door de aanwezigheid van zes mutaties 
kan deze mutant geen twee-dimensionale kristal rooster meer vormen. 
Experimenten uitgevoerd met 2D1-6 lieten zien dat de annexine A5 mutant in 
staat was micro-partikel vorming te remmen. We concludeerden hieruit dat 
remming van micro-partikel vorming door annexine A5 niet veroorzaakt werd 
door het twee-dimensionale kristal rooster. Deze conclusie werd ondersteund 
door de resultaten van experimenten die uitgevoerd werden met annexine A1, 
een lid van de annexine familie die aan PS kan binden maar die geen twee-
dimensionaal kristal rooster kan vormen. We namen waar dat ook annexine A1, 
dosis afhankelijk, de vorming van micro-partikels kon remmen.  
Hoe annexine A5 de vorming van micro-partikels remt is op dit moment niet 
duidelijk. In de afgelopen jaren zijn er artikelen verschenen waarin gemeld werd 
dat, membraan eiwit bevattende, micro-partikels een rol spelen in de 
communicatie tussen cellen en in de overdracht van membraan eiwitten tussen 
verschillende soorten cellen. Een voorbeeld hiervan is de door monocyten (een 
type witte bloed) afgescheiden micropartikels die de membraan eiwitten tissue 
factor (TF) en P-selectine glycoprotein ligand-1 (PSGL-1) bevatten. Er is 
gerapporteerd dat deze micropartikels zich ophopen op bloed-plaatjes die 
aanwezig zijn op plaatsen waar vaatwand beschadiging heeft plaats gevonden. 
Annexine A5 zou een rol kunnen spelen in deze micropartikel gerelateerde 
processen als er aan de volgende voorwaarden voldaan wordt: (1), de 
micropartikels bevatten PS op het membraan oppervlak en (2), de concentratie 
van annexine A5 in het bloed is hoog genoeg om remming van micropartikel 
vorming te veroorzaken.  
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Endocytose van annexine A5 
Gedurende het onderzoek naar de door annexine A5 veroorzaakte remming 
van micropartikel vorming namen we waar dat annexine A5 werd opgenomen 
(endocytose) door cellen met PS op het cel oppervlak. Endocytose was 
afhankelijk van de aanwezigheid van PS op het cel oppervlak omdat annexine 
A5 wel maar de annexine A5 mutant M1234 (welke niet in staat is om PS te 
binden) niet werd opgenomen. Het mechanisme dat verantwoordelijk was voor 
endocytose van annexine A5 was niet gelijk aan macropinocytose of de 
caveolaire en clathrine afhankelijke endocyte. Deze resultaten laten zien dat 
annexine A5 wordt opgenomen via een nieuw endocytose proces.  
Er is gesuggereerd dat annexine A5 in staat is om calcium-ion geleidende 
kanalen in de plasma membraan te vormen. Calcium speelt een rol in signaal 
processen in de cel, het is dus mogelijk dat kanaal vorming van annexine A5 
een rol speelt bij endocytose van annexine A5. Kanaal vorming van annexine 
A5 treed echter alleen op als de calcium concentratie laag is zoals binnen in 
een cel. Buiten de cel, in bloed, treed geen kanaal vorming op zodat het 
annexine A5 geinduceerde endocytose proces niet wordt veroorzaakt door 
kanaal vorming van annexine A5. 
Nadat we hadden uitgesloten dat kanaalvorming van annexin A5 een rol speelt 
in het endocytose process besloten we de rol van het twee dimensionaal kristal, 
gevormd door annexine A5, in het opname proces te bestuderen. We testten de 
betrokkenheid van het twee-dimensionale kristal in het endocytose proces door 
apoptotische Jurkat lymfoma cellen en HeLa tumor cellen te incuberen met 
fluorescente 2D1-6. Analyse van de cellen met behulp van confocale scan laser 
microscopie (CSLM) toonde aan dat de cellen geen fluorescente 2D1-6 hadden 
opgenomen. Uit de resultaten van dit experiment trokken we de conclusie dat 
de vorming van het twee-dimensional kristal noodzakelijk is voor de opname 
van annexine A5 door beide cel typen. Deze conclusie werd ondersteund door 
de resultaten van een experiment met fluorescente annexine A1. We vonden 
dat deze annexine niet werd opgenomen door de apoptotische Jurkat lymfoma 
en HeLa tumor cellen. 
Waarom speelt het door annexine A5 gevormde twee-dimensionale kristal 
rooster een rol in het endocytose proces? De zijde van het annexine A5 
molecuul dat aan negatief geladen PS bind heeft een bolle (convexe) vorm. 
Annexine A5 behoud zijn convexe vorm als het annexine A5 molecuul aan een 
PS bevattende membraan bind en een trimer vormt. We stellen voor dat de 
annexine A5 trimeren, waaruit het twee-dimensionale kristal is opgebouwd, de 
membraan vervormen en ombuigen zodat er endocytische bolvormige 
structuren onstaan binnen in de cel. Annexine A5 veroorzaakt in dit 
hypothetische proces zijn eigen opname door de cel.  
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Annexine A5 veroorzaakt endocytose van tissue factor 
Er is voorgesteld dat annexine A5 een rol speelt in de remming van bloed 
stollings processen. (1) Annexine A5 kan bloed stolling remmen door aan PS te 
binden.  (2) Annexine A5 kan bloed stolling ook remmen door de vorming van 
een twee-dimensionaal kristal op de PS bevattende membraan. Ravassa en 
collega’s hebben voorgesteld dat er nog een derde manier bestaat waarmee 
annexine A5 de bloed stolling kan remmen. Annexine A5 kan de bloed stolling 
ook remmen door internalisatie van tissue factor te veroorzaken op dode cellen. 
Tissue factor (TF) is een eiwit die aanwezig is in de plasma membraan van 
bepaalde cel typen. Dit eiwit is in staat de bloedstollings factor VIIa te binden. 
Het eiwit complex TF en factor VIIa katalyseerd de vorming van actieve factor X 
uit inactieve factor X. De vorming van het complex bestaande uit TF, factor VIIa 
en factor X en de daaropvolgende vorming van factor Xa uit factor X vinden 
plaats als PS aanwezig is in de membraan. 
Er is echter reden tot twijfel dat het  proces voorgesteld door Ravassa en 
collega’s fysiologisch van belang is. Cellen die PS op de plasma membraan 
presenteren worden zeer snel verwijderd door macrofagen. Als het annexine A5 
endocytose proces een rol van belang speelt dan moet het endocytose proces 
plaats vinden voordat de apoptotische cel is verwijderd door macrofagen. We 
onderzochten of endocytose van TF door annexine A5 plaats vindt in levende 
cellen in een model systeem bestaande uit HeLa cellen getransfecteerd met TF 
cDNA. Met dit model systeem lieten we zien dat TF endocytose onder invloed 
van annexine A5 plaats vind door te laten zien dat annexine A5 endocytose van 
fluorescent factor VIIa veroorzaakt in TF cDNA getransfecteerde cellen. Dit 
resultaat laat zien dat annexine A5 niet alleen endocytose veroorzaakt van TF 
in dode cellen maar ook in levende cellen. Annexine A5 veroorzaakte 
internalisatie van TF door dode cellen veroorzaakte een afname in de activiteit 
van TF.  We namen echter geen afname van TF activiteit waar in levende HeLa 
cellen. Dit wordt mogelijk veroorzaakt door recycling van TF na internalisatie 
terug naar het cel oppervlak door levende cellen. In dode cellen treedt geen 
recycling van TF op waarschijnlijk door een defect recycling mechanisme. 
Er zijn de laatste jaren enkele artikelen verschenen waarin gerapporteerd wordt 
dat levende cellen PS op de plasma mebraan presenteren. Twee voorbeelden 
zijn monocyten die differentieren tot macrofagen en monocyten gestimuleerd 
met het eiwit galectine-1. De resultaten die beschreven zijn in hoofdstuk 4 
geven aanleiding tot de gedachte dat annexine A5 bij deze cellen de 
endocytose van TF kan veroorzaken.  
De concentratie van receptoren op de plasma membraan kan gereguleerd 
worden door de caveolaire en clathrine gemedieerde endocytose processen. 
De resultaten die beschreven zijn in hoofdstuk 4 geven aanleiding tot de 
gedachte dat annexine A5 ook betrokken zou kunnen zijn bij de regulatie van 
plasma membraan receptoren. Receptoren die door annexine A5 
geëndocyteerd zouden kunnen worden zijn receptoren die homoloog zijn aan 
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TF zoals de interferon gamma (IFN-γ) receptor of andere receptoren die lid zijn 
van de klasse II cytokine receptor familie. 
 
De functionaliteit van PSGL-1 op apoptotische THP-1 cellen 
In hoofdstuk 5 onderzochten we het effect van veranderingen, die optreden op 
de plasma membraan van apoptotische THP-1 monocyte cellen, op de 
membraan eiwitten TF en PSGL-1. Monocyten kunnen micropartikels 
afscheiden die de membraan eiwitten TF en PSGL-1 bevatten. Dit is alleen 
mogelijk als de eiwitten TF en PSGL-1 zich dicht bij elkaar op de plasma 
membraan bevinden. Omdat annexine A5 de endocytose van TF veroorzaakt 
besloten we te onderzoeken of annexine A5 de functionaliteit van PSGL-1, door 
middel van endocytose, kan beinvloeden. Het onderzoek naar de functionaliteit 
van PSGL-1 tijdens het apoptose proces liet echter zien dat de functionaliteit 
van PSGL-1 verandert zonder dat annexine A5 veroorzaakte endocytose 
betrokken is. Monocyten zijn via PSGL-1 in staat te rollen en te hechten aan 
vast gehechte bloed plaatjes die P-selectine presenteren aan de omgeving. Wij 
toonden aan dat apoptotische THP-1 monocyten niet meer in staat waren te 
rollen en te hechten door dat deze cellen PSGL-1 afscheiden en door dat 
PSGL-1 niet meer vast gehecht was aan het cytoskelet. 
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